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The Hedgehog (Hh) signaling is an important embryonic developmental pathway 
normally responsible for tissue growth, differentiation and patterning. However, aberrant 
activity of this signaling cascade has been implicated in several types of cancer. 
Therefore, inhibition of the dysregulated pathway is a promising therapeutic target for 
treating Hh-dependent malignancies such as basal cell carcinoma (BCC) and 
medulloblastoma (MB). Previous studies resulted in the FDA approval of Vismodegib, a 
small molecule inhibitor of the Hh pathway, for the treatment of advanced BCC. 
Similarly, several other small molecule Hh antagonists have progressed into clinical 
trials. Moreover, several components within the Hh pathway have proven to be 
druggable in ‘proof-of-concept’ studies. Nonetheless, several challenges in the discovery 
and development process for small molecules targeting this pathway have been noted. 
For instance, multiple mechanisms of resistance to Hh inhibitors have been identified. 
This has prompted extensive search for novel inhibitors that function via mechanisms 
that will retain activity in the presence of pathway signaling resistant to current therapy. 
Consequently, a ligand based approach was undertaken to develop Hh inhibitors based 
on two distinct lead structures namely Vitamin D3 (VD3) and Itraconazole (ITZ). An 
interdisciplinary approach utilizing synthetic organic chemistry transformations and 
molecular biology techniques was adopted to study the Hh inhibitory effects of probing 
relevant biological systems with aforementioned small molecule modulators and their 
derivatives. Information thus obtained guided the design of improved second-generation 
Hh inhibitors. A structure-activity-relationship study to identify the Hh inhibitory 
pharmacophore of VD3 was pursued. Based on the findings, VD3 based anti-Hh 
Upasana Banerjee – University of Connecticut, [2014] 
analogues with improved potency and selectivity were designed, synthesized and 
evaluated. Next, a synthetic methodology for preparing ITZ derivatives with 
stereochemically defined hydroxylated side chains was optimized. Preliminary evaluation 
of resultant hybrid ITZ analogues obtained via this synthetic route identified Hh inhibitors 
demonstrating nanomolar potencies. Taken together, the preliminary identification of 
several improved Hh inhibitory scaffolds through these studies will facilitate further 
comprehensive biological evaluation of the promising derivatives. 
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CHAPTER I: Recent Advances in the Design of Hedgehog Pathway Inhibitors for 
the Treatment of Malignancies 
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1. Introduction 
The Hedgehog (Hh) signaling pathway is a developmental pathway that plays an 
essential role in tissue growth and differentiation during embryogenesis. The Hh 
pathway has been implicated in the proper patterning of a variety of human tissues, 
including, bone and cartilage, hair follicles, heart and lung muscle, and the central and 
peripheral nervous system 1. Hh signaling is significantly less active in adult tissues, 
where its primary role appears to be the maintenance of stem cell populations in skin 
and the central nervous system. Aberrant regulation of pathway signaling causes 
constitutive activation, resulting in uncontrolled cellular proliferation and tumor growth; 
most notably in basal cell carcinoma (BCC) and medulloblastoma (MB).  
Hh signaling is primarily controlled by two membrane-bound receptors: Patched 
(Ptch), a 12 transmembrane domain (TM) cell surface receptor; Smoothened (Smo), a 7 
TM G-protein coupled receptor (GPCR)-like receptor; and the glioma-associated 
oncogene (Gli) family of zinc-finger transcription factors, which act in a concerted fashion 
to regulate pathway activity (Figure 1). In the absence of an Hh ligand [Sonic Hh (Shh), 
Indian Hh (IHh), and Desert Hh (DHh)], Ptch represses the activity of Smo through a 
complicated mechanism that is not completely understood. In this state, Gli  and 
Suppressor of Fused (Sufu) form a heteroprotein complex in the cytosol. Sufu serves as 
a negative regulator of Gli by promoting phosphorylation of the Gli proteins, ultimately 
leading to their ubiquitin/proteasome-mediated proteolysis and the generation of N-
terminal truncated forms (GliR) that serve as transcriptional repressors of Hh target 
genes. On binding of an Hh ligand, Ptch is internalized and its inhibition of Smo is 
alleviated. Smo is phosphorylated at its intracellular C-terminus and translocates to the 
cell surface membrane of non-motile cilia. The activation and translocation of Smo 
disrupts the Sufu-Gli complex, leading to the production of intact, active forms of Gli 
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(GliA). GliA acts a transcriptional activator in the nucleus to stimulate production of the 
ubiquitous Hh target genes Gli1, Ptch1, and HHIP (Hh interacting protein). Within the 
context of Hh signaling, GliA primarily consists of Gli2 and/or Gli3, while Gli1 is the 
predominant Hh-responsive activator that mediates the downstream effects of pathway 
activation.  
 
Figure 1. General scheme for the Hh signaling cascade.2 Gli: Glioma-asociated oncogene; 
Hh: Hedgehog; Ptch: Patched; Smo: Smoothened; Sufu: Suppressor of Fused. 
2. Hh Signaling Pathway and Cancer 
2.1 Cellular Mechanisms of Dysregulation 
Aberrant regulation of pathway signaling results in its constitutive activation, 
which can ultimately drive uncontrolled cellular proliferation and tumor growth. While 
multiple mechanisms through which dysregulated or hyperactive Hh signaling 
contributes to tumor formation, growth, and metastasis have been identified, the best 
characterized are Hh ligand independent. These forms of Hh-dependent cancer are 
characterized by mutations in key pathway signal transducers, i.e. Ptch and Smo. Basal 
cell carcinoma (BCC) is the most common human cancer, accounting for ~80% of 
nonmelanoma skin cancers and affecting approximately 10 million people worldwide on 
an annual basis 3, 4. Genetic analyses have demonstrated that a majority of sporadic 
BCCs exhibit detectable genetic mutations in Ptch1 (~75%), Smo (10%), or Sufu (~5%) 
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5, 6. Mutations in Ptch and Sufu have also been implicated as primary factors contributing 
to the development of Hh-dependent medulloblastomas (MB) and rhabdomyosarcomas 
(RMS) 7-10. Studies have also identified several ligand-dependent mechanisms that 
contribute to constitutive pathway activation. These include autocrine, paracrine, and 
reverse-paracrine signaling modalities and have been implicated in a variety of human 
cancers, including pancreatic adenocarcinoma 11-13, gastrointestinal 14, prostate 15-17, 
breast 18, 19, colon 12, 20-22, and hematologic cancers 23, 24. It is important to note that while 
these ligand-dependent mechanisms may contribute to tumor growth in these tissues; it 
is unclear whether cancers that exhibit these forms of aberrant signaling can be defined 
as Hh-dependent. More detailed descriptions of the ways in which Hh signaling 
contributes to human cancer and cancer stem cell populations can be found in several 
recently published review articles 25-30. 
2.2 Resistance to Smo Antagonists 
To date, several Hh pathway inhibitors that target Smo have progressed from 
preclinical development and into clinical trials; however, the development of resistance 
to these compounds has become a major hurdle for their continued development 25. The 
most advanced of these compounds, the small molecule GDC-0449 
(Vismodegib/Erivedge™), was approved by the FDA for the treatment of metastatic 
BCC; however, the trials against MB were less successful 31. Although treatment of an 
MB patient with GDC-0449 also demonstrated initial positive results, relapse occurred 
when a point mutation in Smo (D473H), the molecular target of GDC-0449, rendered the 
patient insensitive to further GDC-0449 treatment (Figure 2A) 32-34. The preclinical 
evaluation of NVP-LDE225, a small molecule pathway inhibitor under development by 
Novartis, in murine models of Hh-dependent MB demonstrated tumor regrowth following 
initial regression, indicating the development of resistance for this compound as well  35. 
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In these studies, treatment with NVP-LDE225 resulted in chromosomal amplification of 
Gli2 and downstream re-activation of Hh signaling, as well as additional point mutations 
in Smo 35. In addition to the development of resistance in MB, a recent study reported 
that 21% of patients receiving continuous GDC-0449 treatment for BCC developed 
regrowth of at least one BCC 36. While the molecular mechanisms that govern this 
secondary acquired resistance have not been described, the results suggest that  
resistance to Smo antagonists in BCC patients will also be an issue moving forward. 
 
Figure 2. Cellular mechanisms of resistance to Hh pathway inhibitors. Gli: Glioma; P-
gp: P-glycoprotein; PI3K: Phosphoinositide 3-kinase; Ptch: Patched; S6K1: S6 kinase 1. 
Additional mechanisms of tumor resistance independent of canonical Hh 
signaling have also been reported for Smo antagonists (Figure 2B). Treatment with IPI-
926 (Saridegib), a semi-synthetic derivative of a natural product Hh pathway inhibitor 
cyclopamine (Cyc), resulted in decreased tumor size and prolonged survival in mouse 
models of MB; however, resistance to this compound also developed 37. In contrast to 
both GDC-0449 and NVP-LDE225, the resistance for IPI-926 was unrelated to either Gli 
amplification or Smo mutations 37. Follow-up studies with IPI-926 linked resistance to 
induction of P-glycoprotein (P-gp) in the tumor cells, suggesting that its decreased 
activity was a result of active efflux from the tumor. MB tumors resistant to NVP-LDE225 
demonstrated upregulation of components in the phosphoinositide 3-kinase (PI3K) 
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pathway 35. PI3K signaling was previously shown to enhance Gli-dependent transcription 
when SHh is present at low levels, suggesting PI3K signaling may partially compensate 
for inhibition of Hh signaling by Smo antagonists to promote tumor resistance 38. In 
esophageal adenocarcinoma (EAC), the mTOR pathway component S6 kinase 1 (S6K1) 
phosphorylates Gli1, resulting in its Smo-independent dissociation from Sufu and 
activation of Hh signaling 39. Although this mechanism has not been explored in other 
Hh-dependent cancers, it provides evidence of another mechanism that is capable of 
promoting resistance to Hh pathway inhibitors that function at or prior to the leve l of 
Smo. The inflammatory cytokine osteopontin (OPN) has also been shown to activate Gli-
mediated transcription through a non-classical mechanism by modulation of Akt/GSK3β 
signaling 40. OPN inactivates GSK3β, which ultimately results in Sufu/Gli dissociation 
and accumulation of GliA within the nucleus. Interestingly, OPN also up-regulated P-gp 
through a Gli-dependent process, suggesting that it may mediate resistance to Smo 
antagonists through multiple distinct mechanisms.  
3. Small Molecule Smo Antagonists 
3.1 Current Status of Important Smo Antagonists  
The first-in-class Hh pathway inhibitor, GDC-0449 (2, Figure 3), was a product of 
collaborative research by scientists at Curis and Genentech 41. A series of iterative 
medicinal chemistry studies optimized the initial lead compound (1, Figure 3) for 
potency, pharmacokinetic (PK) and physicochemical properties to provide GDC-0449 as 
a potent inhibitor of Hh signaling (IC50 values = 3 - 22 nM). Currently, it is approved for 
the treatment of advanced/metastatic BCC unmanageable by surgery or radiation 
therapy 42. As noted above, these initial successes of GDC-0449 have been countered 
by the emergence of resistant forms of Smo that result in its complete loss of efficacy 32. 
Even with the ongoing resistance issues, there is still continued interest in GDC-0449 for 
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several indications as evidenced by currently active clinical trials in which it is being 
studied as both monotherapy or in combination to evaluate its safety and efficacy. 
Moreover, several trials are underway to assess drug interactions and determine 
appropriate drug regimens. Researchers at Genentech seeking to identify structurally-
related compounds that could inhibit Smo D473H and E518K screened a panel of 53 
compounds exhibiting high potency against wild type Smo for their activity against the 
mutant receptors 33. Among these, compound 3 (Figure 3) was selected for further 
evaluation due to its robust activity against both wild-type and Smo D473H (IC50 values = 
300 nM and 700 nM, respectively) and its enhanced half-life (22 hrs). Compound 3 
reduced tumor volume in subcutaneous allografts of the murine Hh-dependent MB tumor 
line SG274 following oral administration (100 mg/kg, once daily [q.d.] dosing); however, 
neither additional studies nor clinical trials for this compound have been reported 33. 
The second small-molecule inhibitor of Hh signaling that has demonstrated 
promising clinical efficacy is NVP-LDE225 (Sonidegib, Erismodegib), a meta-bisphenyl 
carboxamide compound developed by Novartis (5, Figure 3) 43. NVP-LDE225 was 
recently advanced to Phase III studies for advanced BCC and a phase III study for 
relapsed MB is being initiated to study the comparative safety and efficacy of NVP-
LDE225 and Temozolomide (TMZ). Additionally, volunteers are currently being recruited 
to evaluate efficacy against new indications such as resectable pancreatic cancer, 
relapsed acute leukemia, myelofibrosis and Ptch- and Smo-mutant-activated solid and 
hematological tumors. Although clinical resistance has not been reported for NVP-
LDE225, the development of multiple forms of resistance to the compound in mouse 
models of MB remains a critical concern for this scaffold.  
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Figure 3. General structural optimization of GDC-0449 and NVP-LDE225.  
Cyclopamine (6, Figure 4), an alkaloid natural product derived from corn lilies, 
was the first known small-molecule Hh inhibitor. Extensive research using this prototype 
Hh/Smo inhibitor not only led to crucial revelations about multiple binding sites, 
mechanisms of SMO activation and post binding cellular events 44-46, but also pushed 
forward the search for related small-molecule inhibitors for dysregulated Hh pathway 
signaling 44-48. Due to poor physicochemical properties and moderate activity, Cyc was 
unsuitable as a clinical candidate 49; however, second and third generation Cyc 
analogues developed by Infinity Pharmaceuticals improved on the core scaffold and 
ultimately resulted in IPI-926 (7, Figure 4), a clinical candidate that demonstrated 
improved potency and drug-like properties 37, 50. When tested in mouse MB allograft 
models, IPI-926 demonstrated complete regression upon multi-day oral administration 
and abrogated tumor recurrence during a 21-day post treatment period. Despite the 
initial promise, IPI-926 failed to deliver satisfactory results in Phase II clinical trials for 
pancreatic cancer, inoperable chondrosarcoma and myelofibrosis 51. It is important to 
note that, to date, IPI-926 has not been evaluated in forms of human cancer generally 
considered to be Hh-dependent. Although the initial success of IPI-926 suggests the 
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potential clinical efficacy of this class of pathway inhibitor , further development of this 
scaffold has been nominal.  
 
Figure 4. Structures of Cyc and its key analogues.  
Researchers at the University of Pennsylvania described medicinal chemistry 
efforts to identify the Hh inhibitory pharmacophore of Cyc and ultimately developed a 
simplified analogue (8, Figure 4) inspired by the Cyc structure 52. Key modifications 
included replacement of the C-nor-D-homo steroidal structure with an androstane ring 
system, the piperidine ring with a pyridine moiety and homoallyl alcohol by a phenol. 
Analogue 8 and its precursor molecules showed comparable inhibition of Hh signaling in 
reporter gene luciferase assays (IC50 values not reported). Further, analogue 8 was 
equipotent to Cyc in a cell viability assay in MB and three times more potent than Cyc in 
a granule neuron precursors proliferation assay 52. More recently, the preparation and in 
vitro evaluation of a series of Cyc analogues incorporating an exocyclic olefin (9a & 9b, 
Figure 4) were reported by researchers at the University of Leipzig 53, 54. Both analogues 
were significantly more active at inhibiting pathway signaling in Shh-Light II cells, an Hh-
dependent clonal mouse fibroblast cell line incorporating a stably transfected Gli-
dependent luciferase reporter (10- to 25-fold) with the most potent analogue 
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demonstrating an IC50 against Hh signaling of 0.2 µM 
54. Interestingly, removal or 
truncation of the piperidine ring abolished the anti-Hh activity of the exo-Cyc analogues, 
suggesting this functionality is essential for the Hh inhibitory activity of the Cyc scaffold 
54. A comprehensive description of other Cyc analogues can be found in a previously 
reported review 55. 
3.2 Additional Smo Antagonists  
3.2.1 Other Key Smo Antagonists in Clinical Trials 
The results of a medicinal chemistry program at Pfizer designed to improve the 
metabolic profile and enhance the solubility of a class of benzimidazole inhibitors of Hh 
signaling culminated in PF-04449913 (10, Figure 5) a potent, urea-based inhibitor of Hh 
activity (IC50 = 5 nM) 
56. PF-04449913 demonstrated improved PK parameters, including 
a predicted half-life of 30 h and an oral bioavailability of 55% in humans 56. Although 
detailed descriptions of the in vivo activity of this compound have not been disclosed, it 
has been advanced into multiple Phase I and II clinical trials for the treatment of acute 
myeloid leukemia and high-risk myelodysplastic syndrome either alone or in combination 
with other agents. Its efficacy in preventing or decreasing disease relapse in acute 
leukemia patients who have undergone donor stem cell transplant is also a current topic 
of investigation. Researchers at Pfizer have also reported on the preclinical development 
of another potent small-molecule Smo antagonist, PF-5274857 (11, Figure 5) 56. PF-
5274857 specifically binds to Smo, presumably in the GDC-0449/Cyc binding region, 
with high affinity (Ki = 4.6 nM). PF-5274857 demonstrated potent pathway inhibition in 
vitro and in an in vivo model of Hh-dependent MB with IC50 values of 2.7 and 8.9 nM, 
respectively 57. In vivo inhibition of Hh signaling following oral administration (30 and 100 
mg/kg) correlated well with increased survival and significant concentrations of intact PF-
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5274857 was measured in the cerebrospinal fluid, indicating pharmacologically effective 
doses achieved blood-brain barrier penetration 57. 
Researchers at Novartis have recently detailed lead optimization studies on their 
initial substituted phthalazine series that ultimately led to the identification of 1 -
piperazino-4-benzylpyridazine NVP-LEQ506 (12, Figure 5) as a potent pathway inhibitor 
currently in clinical development 58, 59. NVP-LEQ506 demonstrates potent inhibition of 
pathway signaling in vitro against both wild-type and D473H Smo (IC50 values ~1 and 96 
nM, respectively). Competitive displacement assays demonstrated that NVP-LEQ506 
bound with high affinity to human Smo (IC50 = 2 nM) and in vitro PK assays showed its 
enhanced solubility and minimal hERG binding. Preclinical PK studies across multiple 
species demonstrated that NVP-LEQ506 possesses good bioavailability, low clearance, 
and the ability to cross the blood-brain barrier 59. Finally, NVP-LEQ506 reduced Gli 
mRNA expression and promoted tumor regression in a murine allograft of Hh-dependent 
MB following oral dosing (10 – 40 mg/kg, q.d. dosing).  
 
Figure 5. Additional Smo antagonists under clinical development. 
TAK-441 (13, Figure 5) was developed by researchers at Takeda 
Pharmaceuticals by optimizing a novel pyrroloquinoline-one hit compound generated in 
an high-throughput screening (HTS) effort 60-63. During lead optimization, the core N-
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methylpyrrolopyridine scaffold was utilized to achieve optimal PK properties 61. TAK-441 
is a potent inhibitor of Hh signaling in vitro (IC50 = 4.6 nM) that completely abrogated 
tumor growth in an Hh-dependent model of MB following oral administration (25 mg/kg, 
twice daily [b.i.d.] for 14 days) 61.  Interestingly, even though TAK-441 shares the GDC-
0449/Cyc binding site on Smo, it bound wild-type Smo and Smo D473H with comparable 
affinity (Kd values = 1.3nM and 7.8nM respectively) and maintained potent inhibition of 
pathway signaling in vitro in the presence of Smo D473H (IC50 = 79 nM) 
62. In a separate 
study, promising preclinical data was reported in delaying progression of castration-
resistant prostate cancer in vivo (10 mg/kg or 25 mg/kg q.d. dosing for 7 days) 64. 
Athough TAK-441 had advanced into clinical trial, following its initial Phase I Trial, 
Takeda Pharmaceuticals discontinued its development, citing research and development 
priorities in other areas 63.  
LY2940680 (14, Figure 5), a phthalazine-based small molecule Smo antagonist 
under development at Eli Lilly was reported as a potent inhibitor of Hh signaling (IC 50 = 
2.4 nM) as determined in a MB cell line (Daoy) 65. It was also reported to retain 
functional activity against the resistant D473H Smo mutant; however, specific data has 
not been reported in the literature. LY2940680 has also demonstrated efficacy in a 
mouse model of Hh-dependent MB following oral administration and is currently in 
several Phase I & II clinical trials for the treatment of a variety of human cancers 66.  
Exelixis collaborated with Bristol-Myers Squibb to develop XL-139/BMS-833923 
(15, Figure 5) another clinical candidate for Hh inhibition in Phase II trials. It was 
reported to inhibit the expression of Hh signaling markers such as Gli1 and Ptch1 in cell 
lines expressing either wild type or active mutant forms of Smo (IC50 value = 6-35 nM) 
67. 
Competitive binding inhibition of BODIPY-Cyc to Smo by XL-139/BMS-833923 with an 
IC50 of 21 nM was demonstrated by a fluorescence-activated cell sorting-based binding 
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assay. Additionally, it was shown to inhibit in vitro growth of multiple myeloma clones 
and colonogenic growth of several tumor cell lines obtained from hematological cancer 
patients 67. 
3.2.2. Smo Antagonists in Preclinical Development 
Researchers at Merck have disclosed the preclinical development of multiple 
small-molecule scaffolds as Hh pathway inhibitors 68-71. The discovery and development 
of MK-5710 traces its origin to a structure-activity relationship (SAR) study of potent 
bicyclic hydantoin Smo antagonists. Overall, optimization of this scaffold afforded 
homochiral unsubstituted bicyclic tetrahydroimidazo[1,5-a]pyrazine-1,3(2H,5H)-diones 
as Hh pathway inhibitors. The most potent of these, MK-5710 (16, Figure 6) inhibited 
pathway signaling with an IC50 of 17 nM and displaced BODIPY-Cyc from Smo with high 
affinity (IC50 = 13 nM). The in vivo preclinical assessment of MK-5710 revealed favorable 
PK properties (oral bioavailability and low clearance) and potent Hh inhibitory activity 
(40-160 mg/kg, b.i.d.) against a murine allograft model of Hh-dependent MB 69. In 
addition to MK-5710, a collaborative screening and lead optimization effort identified a 
class of piperazinyl ureas as potent inhibitors of Hh signaling 70. The most active 
analogues in this series (17-18, Figure 6) inhibited pathway signaling with IC50 values of 
5 nM and displaced BODIPY-Cyc from Smo (IC50 values = 3 and 13 nM, respectively). 
Further development of this scaffold to improve both potency and PK properties focused 
on iterative modifications to the “left-side” biaryl moiety, the central piperazine, or the 
“right-side” cyclohexyl ring 71. The culmination of these modifications resulted in 
compound 19 (Figure 6), which inhibits Hh signaling with an IC50 of 4 nM and binds with 
high affinity to Smo (IC50 for BODIPY-Cyc displacement = 5 nM); however, further in vitro 
and in vivo characterization of these compounds have not been reported.  
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A collaborative effort from researchers of Novartis, Scripps Institute and Harvard 
University to screen 50K commercially available small molecules for their ability to inhibit 
Hh-Ag 1.5-induced luciferase expression in a stable TM3-Gli-Luc cell line identified 
ALLO-1 (20) and ALLO-2 (21) as potent inhibitors of Hh signaling (Figure 6) 72. Both 
compounds exhibited submicromolar potency in a wide-range of in vitro Hh inhibition 
assays conducted in the TM3-Gli-Luc cells. As an example, IC50 values for ALLO-1 and 
ALLO-2 against Hh signaling induced by overexpression of wild-type Smo were 410 and 
41 nM, respectively. In addition, only a modest two-fold reduction in activity against the 
mouse homologue of Smo D473H (D477G) overexpressed in TM3-Gli-Luc was seen for 
ALLO-1 (IC50 = 1 µM) and ALLO-2 (IC50 = 83 nM) compared to the 175-fold loss in 
potency demonstrated for KAAD-Cyc analogue 72. Anti-proliferation assays in murine 
Ptch1+/-p53-/- MB cells overexpressing wild-type Smo or Smo D477G demonstrated GI50 
values comparable to the IC50 values obtained in the Hh-dependent TM3 cell line. 
Mechanism of action studies suggested that these analogues occupy binding sites on 
Smo distinct from that of either the well-characterized Smo agonist SAG or Cyc. Finally, 
it is noteworthy that ALLO-2 is structurally similar to kinase inhibitors but didn’t 
demonstrate significant inhibition of a 99-kinases panel even when tested at high 
concentrations (5 µM) 72.  
Researchers at Oslo University identified MS-0022 (22, Figure 6) as an Hh 
pathway inhibitor via a screen of 12K compounds for their ability to prevent Hh-
dependent differentiation of C3H10T1/2 cells 73. MS-0022 demonstrated an IC50 of 100 
nM against pathway signaling and modest anti-proliferative effects across several cancer 
cell lines including pancreatic adenocarcinoma, prostate carcinoma and melanoma. A 
decrease in tumor volume of 38% was reported following intraperitoneal (i.p.) 
administration of MS-0022 in a xenograft model of pancreatic adenocarcinoma (50 
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mg/kg, q.i.d.). Studies detailing the mechanism of action for this molecule suggested a 
dual Smo inhibition (IC50 = 259 nM for competitive displacement of BODIPY-Cyc) 
accompanied by micromolar activity against downstream components of the Hh 
signaling cascade. Further experiments are warranted to clarify the specific molecular 
effects of this compound 73.  
Screening of the Novartis chemical compound collection resulted in the 
identification of LAB687 (23a, Figure 6) as a micromolar inhibitor of Hh signaling (IC50 
1.2 µM). Interestingly, this molecule had been originally synthesized as a nanomolar 
inhibitor (IC50 0.9 nM) of microsomal triglyceride transfer protein (MTP). As SAR studies 
were carried out to prepare selective Hh antagonist based on this scaffold, two 
derivatives exhibiting nanomolar Hh inhibition and minimal MTP activity measured were 
generated. In a Gli-luciferase reporter gene assay in TM3 cells, IC50 values for LAB687 
derivative 1 and LAB687 derivative 2 (23b and 23c, Figure 6) were calculated to be 8 
nM and 17nM respectively 74. It is noteworthy that this class of ortho-bisphenyl 
carboxamide is closely related to clinical candidate NVP-LDE225 that represents the 
meta-bisphenyl carboxamide family of analogues. 
uHTS screening of Wuxi’s screening collection utilizing Shh-Light II cells 
amounted to the identification and development of 4-[3-(quinolin-2-yl)-1,2,4-oxadiazol-5-
yl]piperazinyl urea class of analogues. Optimization of this class was performed through 
SAR study leading to improved derivatives Wuxi 91 and Wuxi 94 (24a and 24b, Figure 
6). Both analogues demonstrated IC50 values of 5 nM in Gli-dependent reporter gene 
assay conducted in Shh-Light II cells. Smo binding IC50 values for these derivatives 
when measured in presence of 2% FBS were determined to be 3 nM and 13 nM for 
Wuxi 91 and Wuxi 94 respectively. However, based on PK assessment of the potent 
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derivatives, Wuxi 94 was shown to possess better intrinsic clearance rate in rats and 
dogs 70. 
 
 Figure 6. Structures of synthetic Smo antagonists in preclinical development. 
A high content screen of FDA approved drugs, clinical candidates, and small 
molecules with known biological activity was conducted by researchers at Harvard 
University to identify compounds that inhibited Smo accumulation in the primary cilia 75. 
This screen identified two small molecules, DY131 (25, Figure 7) and SMANT (26, 
Figure 7), as modest inhibitors of pathway signaling (IC50 values = 0.8 – 2 and 1.1 – 3 
µM, respectively). DY131 was originally prepared as an Estrogen Related Receptor 
agonist, but within the context of Hh inhibition it was shown to function via direct binding 
to Smo at the GDC-0449/Cyc binding site (as measured by displacement of BODIPY-
Cyc). In addition, inhibition of Hh signaling by DY131 was significantly reduced in the 
presence of a ligand-independent, oncogenic mutant of Smo (SmoM2). By contrast, 
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SMANT functionally inhibited Hh signaling induced by both wild-type Smo and SmoM2 at 
comparable concentrations and did not compete for Smo binding with Cyc, suggesting a 
novel mechanism of action for this scaffold 75.  
 
Figure 7. Structures of synthetic Smo antagonists in preclinical development. 
A similar high-content screen designed by scientists at the University of 
California at San Francisco to select small molecules that inhibit Smo translocation to 
the cilia and/or ciliogenesis identified ten compounds including SA1 and SA4 (27a and 
27b respectively, Figure 7) as modest inhibitors of Hh signaling (IC50 value range 0.92 – 
19 µM) that function via inhibition of Smo localization in the cilia 76. All ten compounds 
reduced Gli1 mRNA expression in Ptch1-/- mouse embryonic fibroblasts (MEFs) and 
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BCC cells, but only compounds SA1-9 displaced BODIPY-Cyc from Smo, demonstrating 
that they function via direct binding to Smo. Nonetheless, although SA10 (27c, Figure 7) 
did not displace BODIPY-Cyc, it was inactive in Sufu-/- cells, indicating that it also 
functions at the level of Smo, albeit through an undefined mechanism. In addition, SA1-
10 (25 µM) inhibited Hh signaling in the presence of the oncogenic SmoM2 construct. 
Finally, this screen also identified two other small molecules that inhibited ciliogenesis; 
however, neither of these compounds inhibited Hh signaling in cell culture 76.    
Based on the knowledge that many of the Smo antagonists share structural 
features and bind in the same location on the receptor, a small molecule Smo antagonist 
pharmacophore was generated and used by a group at the Centre National de la 
Recherche Scientifique as the basis for a virtual screening effort to identify novel 
inhibitory scaffolds 77, 78. Based on the screening results, the acylthiourea MRT-10 (28a, 
Figure 7) and its corresponding acylurea MRT-14 (28b, Figure 7) were synthesized and 
validated as Hh pathway inhibitors (IC50 values = 0.64 and 0.16 µM, respectively) 
77. In 
addition, both MRT-10 (IC50 = 0.5 µM) and MRT-14 (IC50 = 0.12 µM) displaced BODIPY-
Cyc from Smo at concentrations that correlated well with their Hh inhibitory activity. 
Additional medicinal chemisty studies on this scaffold resulted in the identification of 
MRT-83 (29, Figure 7), which demonstrated an enhanced ability to inhibit Hh signaling 
(IC50 = 15 nM), prevent proliferation of cerebellar granule cell precursors (IC50 = 6 nM), 
and displace BODIPY-Cyc from Smo (IC50 = 5 nM) 
78. 
A fragment-based design approach was applied towards the discovery and 
development of novel N-(2-pyrimidinylamino) benzamide derivatives as potent inhibitors 
of Hh signaling by researchers at Jiangsu Pharmaceutical 79, 80. Combining key structural 
features of Smo antagonists such as ALLO-2 and NVP-LDE225, lead compound 6a (30, 
Figure 7) was designed and synthesized 79. Interestingly, this compound exhibited 
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greater potency (IC50 = 1.3 nM) as compared to NVP-LDE225 (IC50 5.5 nM) and GDC-
0449 (IC50 7.2 nM) in Hh-dependent cells. Extensive SAR studies guided modifications 
to the terminal aromatic rings ultimately resulted analogue 3c (31, Figure 7), which 
demonstrated comparable potency (IC50 1.3 nM) and improved permeability (AlogP 3.6) 
80. Continuing the search for improved leads based on this scaffold, an additional series 
of analogues incorporating a pyrrolotriazine isostere in lieu of  the pyrimidine was 
prepared and evaluated. Many of the derivatives from this class demonstrated potent Hh 
inhibition (IC50 range 0.62 – 12.3 nM); most notably, compound 19a (32, Figure 7) not 
only exhibited potent anti-Hh activity (IC50 = 0.83 nM), but also superior in vivo plasma 
exposure and an increased half-life 81. To date, additional in vitro assays or in vivo 
studies to assess Hh inhibitory efficacy and tumor regression have not been reported for 
these compounds. 
Several sterol based Smo antagonists have also been recently identified by 
several different academic research groups 82-84. The azasterol 22-NHC (33, Figure 8) 
inhibits Hh signaling with an IC50 of 3 µM and does not affect the interaction between 
Smo and other known Smo inhibitors acting on the TM region of Smo 82. The synthetic 
glucocorticoids Budesonide (34a) and Ciclesonide (34b) were identified as pathway 
inhibitors through their ability to inhibit Smo ciliary accumulation (Figure 8) 83. In a panel 
of in vitro assays, Budesonide demonstrated modest and comparable inhibition of 
pathway signaling against both wild-type and D473H Smo (IC50 values ~50 µM). The 
sterol-based Smo antagonists, 20(R)-yne (35) and 20-keto-yne (36), were identified as 
modest Hh pathway inhibitors with IC50 values of approximately 5 – 10 µM (Figure 8) 
84. 
In addition, both 35 and 36 inhibited Smo D477G-mediated pathway inhibition at levels 
comparable to their inhibition of wild-type Smo (~75% inhibition of signaling at 25 µM). 
Follow-up studies for these sterols have demonstrated that, in contrast to the Smo 
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antagonists described above, each of these function through direct binding to a newly 
identified binding site on the extracellular cysteine rich domain of Smo (CRD, described 
in more detail in Section 3.3 below).  
 
Figure 8. Sterol related Smo antagonists.  
3.3 Identification and Mapping of Smo Binding Sites  
Numerous groups have actively sought to probe several distinct small molecule 
binding sites on Smo in order to: (i) facilitate the rational design of future Smo 
antagonists; and (ii) better understand to what extent endogenous small molecules 
regulate pathway signaling via direct binding to Smo 82-88. More detailed information on 
Smo binding sites could potentially mitigate the problem of drug resistance and permit 
combination therapy or allosteric modulation for improved potency. The first attempts to 
identify a small molecule binding region on Smo utilized photoaffinity labeling studies 
with an azide-I125 labeled Cyc analogue and deletion mutants of Smo to localize the Cyc 
binding pocket to the heptahelical bundle of Smo 46. Since that time, a similar BODIPY-
labeled Cyc analogue has been routinely utilized to demonstrate that multiple small 
molecule Smo antagonists and agonists bind in the same region as Cyc. Further 
information on the GDC-0449/Smo binding site came with the identification that the Smo 
D473H mutant resulted in the loss of both affinity and efficacy. Further evidence to 
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corroborate this binding site was achieved by mapping the location of D473 to the C-
terminal end of transmembrane loop 6 on a rhodopsin-based molecular model of Smo 34. 
Indeed, the Asp residue was found to occupy an extracellular site facing the central 
binding cavity of Smo. Interestingly, this position is a highly conserved region among 
Smo orthologs and Wnt signaling proteins that belong to the Frizzled family 87.  
Table 1. Key Hh pathway inhibitors that function through direct inhibition of Smo. 
Compound 
IC50 
wild-type Smo
a
 
IC50 
D473H/D477G
a
 
Development Status Reference 
GDC-0449 3-22 nM Loss of activity Clinically Approved 41 
IPI-926 7 nM 244 nM Clinical (Phase II) 37, 50 
NVP-LDE225 2.5 nM Loss of activity Clinical (Phase III) 43, 89 
PF-04449913 5 nM ND Clinical (Phase II) 56 
NVP-LEQ506 1 nM 96 nM Clinical(Phase I) 59 
TAK-0441 4.6 nM 79 nM Clinical (discontinued) 61, 62 
LY2940680 2.4 nM Active
b
 Clinical (Phase II) 66 
XL-139/BMS 21 nM ND Clinical (Phase II) 67 
PF-5274857 2.7 nM ND Preclinical 57 
MK-5710 17 nM ND Preclinical 69 
19 5 nM ND Preclinical 71 
ALLO-1 410 nM 1 µM Preclinical  72 
ALLO-2 41 nM 83 nM Preclinical 72 
MS-0022 100 nM ND Preclinical 73 
LAB 687 1.2 µM  ND Preclinical 74 
23b 8 nM  ND Preclinical 74 
23c 17 nM ND Preclinical 74 
Wuxi 91 5 nM ND Preclinical 70 
Wuxi 94 5 nM ND Preclinical 70 
DY 131 0.8-2 µM ND Preclinical 75 
SMANT 1.1 – 3 µM ND Preclinical 75 
MRT-83 15nM ND Preclinical 78 
32 0.83 nM ND Preclinical 81 
33 3 µM ND Preclinical 82 
Budesonide 50 µM 50 µM Preclinical 83 
35 5-10 µM ~30 µM Preclinical 84 
36 5-10 µM ~30 µM Preclinical 84 
a
 Values assessed using different assay methods described in text 
b 
Specific IC50 values were not provided 
ND=not determined/ reported 
 More detailed structural information about the small-molecule binding site(s) on 
the 7TM domain region of Smo has come from two recently published co-crystal 
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structures describing this region in complex with either LY2940680 87 or Cyc 88. A lipidic 
mesophase method was utilized to solve a co-crystal structure of an engineered human 
Smo receptor in complex with LY2940680 to 2.5 Å (Protein Data Bank ID 4JKV) 87. The 
overall structure of Smo is characterized by an elaborate arrangement of long 
extracellular loops that are stabilized by four disulfide bonds and within this context,  the 
binding pocket of LY2940680 is at the extracellular end of the 7TM helical structure and 
is linked to the extracellular environment by a small opening characterized by the 
extracellular domain and extracellular loops 2 and 3. Two water molecules form a 
structured hydrogen-bonding network between R400, H470, D473, E518, and N521 that 
help define the binding pocket; however, they do not make direct interactions with 
LY2940680. Key hydrogen-bonding interactions occur between the guanidinium of R400 
and the phthalazine nitrogens and between the carboxamide of N219 and the carbonyl 
oxygen. Direct contact between LY2940680 and D473 is minimal (4.04 – 4.31 Å 
between the aspartic acid carboxylate and the Smo antagonist) and these limited 
interactions help to explain how the compound retains potent activity in  the presence of 
Smo D473H (Figure 9). More recently, a lipidic cubic phase method was utilized to solve 
the co-crystal structure of Cyc in complex with the same engineered human Smo 
receptor (3.2-4.0 Å) 88. The Cyc binding region was localized to the same vicinity as 
LY2940680; however, the low resolution of the complex prevented the definitive 
identification of the Cyc orientation within the binding pocket. The authors provide 
evidence that the pyridine ring is positioned towards the solvent exposed extracellular 
space of the binding region, but further refinement is necessary to conclusively identify 
the binding site and key molecular interactions between Cyc and Smo.      
In addition to small molecule binding sites within the 7TM domain of Smo, 
several independent research groups have explored the ability of Hh pathway 
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modulators to exert their activity through direct binding interactions with the extracellular 
cysteine rich domain (SmoCRD) 82-86. These studies have all focused on exploring the 
role of the SmoCRD in binding Hh agonists and antagonists with a sterol or sterol-like 
scaffold. Initial assays utilizing Smo deletion and/or ligand affinity protocols 
demonstrated that the Hh agonist properties of oxysterols (OHCs) are mediated through 
direct binding to the SmoCRD and that small molecules that bind in this location can be 
agonists or antagonists, depending on structure 82-85. In addition, these experiments 
provided strong evidence that the OHC binding site is localized to “site 1” of the CRD, a 
hydrophobic pocket formed by side chain α-helices that is analogous to the lipid-binding 
grove previously identified in the Frizzled CRD. Two recent reports have provided 
additional detailed structural insights into this small molecule binding site via the crystal 
structure of the zebrafish SmoCRD (zSmoCRD, 2.3 Å resolution) 84 and the NMR 
solution structure of the Drosophila SmoCRD (dSmoCRD) 86. Molecular docking studies 
between zSmoCRD and 20(S)-OHC, a well-characterized pathway agonist, suggested 
the tetracyclic core of the OHC scaffold lies in the base of the lipid-binding groove at site 
1 lined by W87 and L90. This docking model predicts that the 3β-hydroxy of 20(S)-OHC 
orients towards helix 1 residues L90 and N92, while the 20(S)-hydroxy and side chain 
are in close proximity to residues P142 and F144 84. Mutagenesis studies on residues 
within the predicted binding site supported the structure-based model of the OHC 
binding pocket; however, specific molecular interactions between the OHC scaffold and 
these residues have not been detailed 84. The solution structure of Budesonide in 
complex with dSmoCRD further supports the site 1 lipid-binding groove as the key 
binding pocket for sterol-based pathway modulators of Hh signaling within the CRD 86. 
Chemical shift perturbations identified potential binding interactions between budesonide 
and R161, W109, G111, and L112, all of which reside within site 1 and were previously 
identified as key for 20(S)-OHC binding.  
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Figure 9. Key binding site interactions between Smo and LY2940680. 
4. Small Molecule Non-Smo Antagonists 
4.1 Compounds Acting Upstream of Smo 
Maturation of a fully active Hh ligand results from a series of post-translational 
modifications of the secreted protein, including the covalent attachment of a palmitoyl 
moiety at the N-terminus 90. For this modification, hedgehog acyltransferase (Hhat) 
catalyzes the attachment of a palmitoyl group to the N-terminal cysteine of SHh through 
an amide bond. A high-throughput screen (~64K compounds) was conducted to identify 
small molecules that inhibit Hhat-mediated SHh palmitoylation 91. Secondary analysis of 
the hit compounds to identify potent inhibitors with promising drug-like properties 
identified four structurally-related thiophene piperidines with IC50 values ranging between 
0.2-5µM. One compound RU-SKI 43 (37, Figure 10) with an IC50 of 0.85 µM was chosen 
for further evaluation as a Hhat inhibitor. It was a noncompetitive inhibitor (Ki = 6.9 µM) 
with respect to [I125] iodo-palmitoyl CoA and an uncompetitive inhibitor with respect to 
SHh; moreover, inhibition by RU-SKI 43 was selective to Hhat and not a broad activity 
against other fatty acyltransferases. Finally, several cellular assays demonstrated that 
the Hh inhibitory activity of RU-SKI 43 is mediated at the level of SHh 91.   
Several macrolactones that inhibit Hh signaling through direct binding to SHh 
were identified in a microarray-based screen (10K compounds) by researchers at the 
Broad Institute 92. Optimization of the lead scaffold led to robotnikinin (38, Figure 10), 
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which bound to SHhN (an active N-terminal fragment of SHh) with a Kd value of 3.1 µM 
as determined via surface plasmon resonance. Binding to Hh ligand is thought to induce 
conformational changes in the protein preventing its interaction with Ptch and repressing 
SHh-mediated Gli overexpression. When tested in a Gli-luciferase reporter gene assay 
in Hh-dependent cells, it inhibited Hh signaling with an IC50 of 4 µM 
92. Further SAR 
studies on the macrolactone scaffold produced a series of analogues including 
BRD6851 (39, Figure 10), as an Hh inhibitor with improved activity (IC50 = 0.4 µM) 
93. 
Interestingly, cellular studies into the mechanism of BRD6851 suggested it functions at 
the level of Smo; however, these studies were indirect and displacement of a known 
small molecule Smo antagonist by BRD6851 has not been demonstrated. To date, in 
vivo data in Hh-dependent models of cancer have not been reported. 
 
Figure 10. Structures of inhibitors upstream of Smo. 
Computational approaches to design small molecules that perturb SHh/Ptch 
binding interactions have been undertaken at Gyeongsang National University in Korea 
94, 95. First, robotnikin and related analogues were used to develop a 3D-pharmacophore 
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model that was used in a virtual screening of >100K to identify structurally-related small 
molecules as possible Hh pathway inhibitors 94. This screen and follow-up modeling 
studies suggested that GK 03795 (40, Figure 10) should bind SHh in the same location 
as robotnikin. A second virtual screen of >200K utilizing a computational model of key 
SHh/Ptch binding interactions was performed to identify small molecules that disrupt this 
specific interaction. Additional docking and computational analysis of two hit compounds, 
BAS 13382637 (41) and BAS 06350510 (42), suggest their potential to bind SHh with 
high affinity (Figure 10) 95. To date, experimental verification of these simulation results 
in in vitro or in vivo assays has not been reported. 
4.2 Compounds Acting Downstream of Smo 
Two small molecules, GANT-58 & GANT-61 (43 & 44, Figure 11), were identified 
as inhibitors of Gli-mediated transcription through a screen in HEK293 cells 
overexpressing Gli1 by researchers at the Karolinska Institutet 96. Both compounds 
inhibited Hh signaling and Gli expression with an IC50 value of approximately 5µM 
96. 
Their ability to maintain potent Hh antagonism in Sufu -/- cells verified that these agents 
act downstream of Smo. Interestingly, GANT-61 was shown to disrupt Gli1 DNA binding 
in live cells.  Selectivity for Hh-mediated Gli expression was corroborated using a 
microarray analysis in which neither analogue was active against several unrelated 
signaling pathways. In addition, both compounds prevented the formation of dominant-
active Smo transfected NIH3T3 colonies in soft agar. Finally, tumor growth regression 
and significant decrease in Ptch mRNA level were observed upon treating a mouse 
xenograft model of human prostate cancer with GANT-61 (s.c., 2.5 mg/kg, once daily 
dosing for 18 days) 96. 
Studies demonstrating interactions between Gli proteins and the transcriptional 
coactivator TBP-associated factor 9 (TAF9) prompted the design of a small molecule, 
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FN1-8 (45, Figure 11), which prevents Gli/TAF9 interactions and down-regulates Gli 
expression 97. The structure of this compound developed by researchers at the 
University of California at San Francisco was derived as a mimic of the common α-
helical ‘FXXɸɸ’ motif contained in many Gli proteins. FN1-8 (15 µM) prevented TAF9 
from binding both Gli1 and Gli2 in vitro and led to significant reductions in Gli 
transcriptional activity 97. FN1-8 (7.5 or 15 µM) prevented proliferation of non-small cell 
lung cancer cells (NSCLC) that over-express either Gli1 or Gli2 and its anti-proliferative 
effect correlated well with down-regulation of endogenous Ptch and Gli1 mRNA. Finally, 
FN1-8 down-regulated Ptch and Gli1 mRNA and reduced tumor volume in NSCLC 
xenografts (50 mg/kg, sc) 97. Subsequent modifications to FN1-8 carried out at St. Jude 
Children’s Research Hospital afforded a modest inhibitor of Gli1 transcription factors 
known as NMDA298-1 (46, Figure 11). Extensive SAR for the scaffold demonstrated that 
the tyramine amide region of this chiral molecule is essential for its biological activity. 
NMDA298-1 activity was selective for Gli1 compared to Gli2 in Hh-dependent cell culture 
(IC50 values = 6.9 and ~23.9 µM, respectively). Additional viability studies in cancer cells 
(breast, MB, prostate cancer, Burkitt’s lymphoma, hepatocarcinoma, glioma) versus 
healthy cells (human skin fibroblasts) established that NMDA298-1 selectively targets 
tumor cells 98.  
Historically, arsenicals have been known for their toxicological effects during 
embryogenesis; however, arsenic trioxide (ATO) has had pharmacological use in the 
clinic as a curative agent for acute promyelocytic leukemia 99. Based on these seeming 
contradictions, the role of several arsenicals in inhibiting Hh signaling was evaluated by 
researchers at the Stanford University School of Medicine. Three arsenicals (sodium 
arsenite, ATO, phenylarsine oxide) and the most active, ATO, inhibited pathway activity 
in an Hh-dependent cell model with an IC50 value of 0.7 µM 
100. In murine allografts of 
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Hh-dependent MB, ATO inhibited tumor growth in a dose-dependent fashion following IP 
administration (2.5 – 10 mg/kg). In addition, ATO inhibited Smo D477G-mediated Hh 
signaling at a level comparable to that for wild-type Smo (IC50 = ~0.8 µM). ATO as a 
monotherapy and in combination with other Hh pathway inhibitors has demonstrated 
potent anti-Hh and anti-tumor effects in a variety of in vivo models of Hh dependent 
cancer 100-102. Most notably, ATO increased survival in an orthotopic model of MB driven 
by Smo D477G (IP administration, 7.5 mg/kg, OD) 101. Mechanistic studies on the target 
of ATO within the Hh pathway have demonstrated that it directly binds to Gli1, reducing 
its transcriptional activity and decreasing expression of Gli target genes 100, 102.    
 
Figure 11. Synthetic Hh pathway inhibitors that target downstream of Smo. 
  The pathway inhibitors HPI-1 through HPI-4 (47, 48a-c, Figure 11) were 
identified at the Stanford University through a screen of >100K compounds specifically 
for their ability to interfere with Hh signaling downstream of Smo 103. Each of these 
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compounds demonstrated modest inhibition of Hh signaling with an IC50 value range of 
1.5 - 7 µM. In addition, these compounds demonstrated selectivity for Hh signaling over 
Wnt, PKA and PI3K/MAPK signaling. Interestingly, while each HPI was able to inhibit 
pathway activity in the presence of the SmoM2 mutant, only HPI-1 and HPI-4 prevented 
SmoM2-dependent proliferation of cerebellar granule neuron precursors. The HPIs are 
structurally dissimilar and antagonize the hyperactive signal transduction through varied 
subcellular mechanisms even though they all target components downstream of Smo. 
The central theme underlying their inhibitory activity is disturbing the processing, 
trafficking and stability of Gli transcription factors 103. In order to enhance the solubility 
and bioavailability profile of HPI-1, researchers at the Johns Hopkins University 
formulated it as a polymeric nanoparticle with poly(lactic-co-glycolic acid) conjugated to 
polyethylene glycol (PLGA-PEG) to provide NanoHHI 104. In contrast to HPI-1, NanoHHI 
formed a uniform suspension in aqueous media, was orally bioavailable, and crossed 
the blood-brain barrier 104. NanoHHI reduced tumor volume in orthotopic models of MB 
driven by either wild-type Smo or Smo D477G (IP administration, 30 mg/kg, b.i.d) 104. In 
addition, NanoHHI inhibited in vitro proliferation and in vivo tumor growth and metastasis 
of hepatocellular carcinoma 105.  
Naturally occurring flavonoid glycosides from Excoecaria agallocha leaves inhibit 
the Hh signal transduction by abrogating Gli1 translocation to the nucleus. Researchers 
at Chiba University reported that compounds 1, 2 and 8 (49a-c, Figure 11) antagonize 
Gli mediated transcriptional activity with IC50 values of 0.5, 19.1 and 2.0 µM respectively. 
In addition, these compounds exhibit selective cytotoxicity against human pancreatic 
cancer cells (PANC1) and human prostate cancer cells (DU145) at low micromolar 
concentrations.  Further investigation revealed that compound 1 inhibited the expression 
of Hh proteins (Ptch and BCL-2) and blocked nuclear translocation of Gli1 in PANC1 
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cells in a dose dependent fashion. Further, experiments with siRNA mediated 
knockdown of Smo confirmed that Gli1 inhibition is brought about independently of Smo 
interference 106. 
4.3 Compounds With Unknown/Undisclosed Target or Indirect Mechanism 
Several members of the vitamin D class of secosteroids have also been identified 
as modulators of Hh pathway signaling. Vitamin D3 or VD3 (50, Figure 12), a metabolic 
precursor to the hormonally active form of vitamin D known as calcitriol, was first 
identified as a pathway inhibitor in studies conducted to identify physiological small 
molecules that control Ptch-mediated inhibition of Smo 107. VD3 inhibition of Hh signaling 
in vitro is modest, with IC50 values reported between 1 and 20 µM 
107-111. VD3 has 
demonstrated the ability to significantly reduce in vitro proliferation of Hh-dependent 
BCC cell lines and reduce in vivo Gli expression in mouse models of BCC 110. 
Interestingly, while VD3 inhibited the growth of pancreatic cancer cells, it failed to have 
an anti-tumor effect in a comparable xenograft model of pancreatic adenocarcinoma 109. 
Initial studies into the mechanism of action for VD3-mediated Hh inhibition suggested 
that this activity was at the level of Smo; however, it has also been shown that VD3 can 
activate canonical vitamin D receptor (VDR) signaling in these same model systems 108-
110. Calcitriol (51, Figure 12), generally acknowledged as the physiologically active form 
of vitamin D, has also demonstrated the ability to inhibit Hh signaling in vitro and in vivo 
in Hh-dependent models of BCC and RMS. Similar to VD3, calcitriol appears to inhibit 
Hh signaling at the level of Smo, while also activating the canonical VDR pathway in 
these models. Taken together with the additional recent data suggesting complicated 
crosstalk between Hh and VDR signaling (reviewed in a previous publication 112), further 
explorations into the biological activities of these secosteroids is warranted to more 
clearly define the mechanisms that govern their pathway modulation.  
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A medicinal chemistry approach undertaken at the University of Connecticut to 
design analogues of VD3 that selectively target Hh signaling demonstrated that the 
‘northern’ region of VD3, also known as Grundmann’s alcohol (52, Figure 12), retains 
~90% of the Hh inhibitory activity of the parent scaffold (IC50 values = 3.1 and 4.1 µM, 
respectively) 111, 113. A subsequent series of VD3 analogues designed to incorporate an 
aromatic A-ring isostere that maintains the approximate steric and hydrophobic features 
of the natural aliphatic A-ring into the secosteroid scaffold identified compound 53 
(Figure 12) as a selective Hh inhibitor with improved potency (IC50 = 0.74 µM) 
113, 114. 
 
Figure 12. Compounds with indirect/unknown/undisclosed mechanism(s). 
Desmethylveramiline (54, Figure 12), a semi-synthetic compound, belongs to the 
steroidal family of Hh inhibitors and shares structural features with Cyc. A seven step 
derivatization of teratogenic alkaloid veramiline was reported by researchers at 
University of Strasbourg. Using relatively straightforward synthetic manipulation of 
commercially available starting material, Fernholtz acid, preparation of this analogue 
was accomplished with the intention to mimic the complex spatial structure of Cyc 115. At 
10 μM, it inhibited ShhN-induced luciferase activity in Shh-Light II cells and SAG-induced 
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differentiation of C3H10T1/2 cells by 87 ± 1% and 85 ± 4% respectively.  However, the 
specific molecular target of this micromolar inhibitor remains undetermined to date. 
A screen of FDA approved drugs identified the clinically efficacious antimycotic 
drug itraconazole (ITZ, 55, Figure 12) as a potent pathway inhibitor in vitro (IC50 values = 
270 – 690 nM, depending on cellular context) 116. ITZ also inhibits pathway signaling 
mediated by Smo D477G at a level comparable to its inhibition of wild -type Smo (IC50 
~500 nM) 101. Treatment with ITZ significantly decreased tumor volume and increased 
survival in Smo D477G MB allografts. In addition, oral administration of ITZ (75 mg/kg, 
b.i.d) significantly increased survival in an orthotopic model of MB expressing 
SmoD477G, highlighting the ability of ITZ to be centrally active against intracranial 
tumors. Similar activities for ITZ in Hh-dependent BCCs have also been described 101, 116. 
Studies have demonstrated that the Hh inhibitory activity of ITZ is unrelated to inhibition 
of 14-α-lanosterol demethylase, the physiological target responsible for its anti-fungal 
properties. Further investigations have suggested that it inhibits at the level of Smo; 
however, direct binding interactions or displacement of a known Smo antagonist have 
not been identified. The results of a Phase II trial into the anti-BCC effects of oral ITZ 
demonstrated positive results and the authors note further clinical trials are in the 
planning process 117. It should be noted that ITZ was also recently identified as an 
inhibitor of angiogenesis, suggesting its potential application as an anti -cancer 
therapeutic via multiple distinct mechanisms of action 118, 119. A single publication 
detailing Hh inhibitory activity for ITZ analogues with modified alkyl side chains has been 
reported 120. These studies demonstrated while small aliphatic groups were well-
tolerated, bulky functional groups in this region completely abolished inhibitory activity.  
 A recent screen of approximately 20K small molecules followed by SAR studies 
on the hit scaffold conducted at the Broad Institute of MIT and Harvard University 
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identified a series of small molecules that incorporate a central eight -membered 
heterocycle as inhibitors of pathway signaling 121. The most potent compounds that also 
demonstrated promising drug-like solubility, BRD50837 and BRD9526 (56 and 57, 
Figure 12), were chosen for additional studies to probe the mechanism of action of this 
scaffold (IC50 values = 90 and 60 nm, respectively). Neither compound displaced 
BODIPY-Cyc from Smo, suggesting they did not bind in the known Smo binding pocket. 
Interestingly, while neither compound inhibited pathway signaling in Ptch -/- cells, they 
retained partial activity in SuFu-/- cells, a seemingly contradictory result 121. It is clear 
that further studies are warranted to understand the cellular mechanisms that govern the 
Hh inhibitory activity of this scaffold.  
Researchers at Novartis recently combined a high-throughput screening effort 
with additional in vitro assays to identify novel small molecule modulators of Hh signaling 
122. Their overall goal was to identify ‘non-Smo’ inhibitors that could then be utilized as 
chemical probes to identify new drug targets within the pathway. The ultimate result of 
these studies was the identification of the cyclohexyl-methyl aminopyrimidine (CMAP) 
scaffold represented by 58, 59, and 60 (Figure 13) as inhibitors of Gli-mediated 
transcription that function via agonism of the orphan GPCR GPR39. These three 
compounds potently inhibited Hh signaling (as measured by down-regulation of a Gli 
luciferase reporter) with low nanomolar potency (IC50 values = 4 -10 nM) 
122. Follow-up 
studies with these compounds demonstrated that GPR39 was required for their anti -Hh 
activity and it was hypothesized that activation of GPR39 stimulates multiple signaling 
pathways to activate MAPK, which directly inhibits the transcriptional activity of Gli 
proteins 122.   
Researchers at Chiba University reported three naturally occurring molecules 
namely colubrinic acid, betulinic acid and alphitolic acid (61, 62 and 63, Figure 13) found 
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in pentacyclic triterpenoids of Zizyphus cambodiana to exhibit Hh inhibitory activity 123. 
These compounds inhibit Gli1 expression with micromolar IC50 values (38-42 μM) and 
also exert cytotoxic effects on pancreatic and prostate cancer cells. On the contrary, 
they are relatively non-lethal towards non-cancerous cells such as MEFs. Interestingly, 
inhibition of Hh signaling by betulinic acid in rhabdomyosarcoma cells is accompanied by 
induction of apoptosis 123, 124. This pharmacological effect could be due to its role in 
activation of the Mitogen Activated Protein Kinase (MAPK) pathway as established 
earlier in human melanoma cells 125. Nonetheless, antagonism of Hh signaling was 
confirmed by documenting reduction of Hh target genes such as Gli1, Gli2, Ptch1 and 
IGF2 in a rhabdomyosarcoma cell line with otherwise increased Hh pathway activity.   
Structurally distinct compounds GW3965 and TO-901317 (64 and 65, Figure 13) 
are liver X receptor (LXR) agonists that indirectly antagonize the Hh signaling 126. 
Researchers at University of California Los Angeles recorded a dose-dependent and 
time-dependent inhibition of Hh responsive genes (Ptch1, Gli1) following treatment in 
MEF M210B4 cell line. Using qRT-PCR, greater than 50% inhibition of Ptch1 and Gli1 
expression was observed upon treatment with 2 μM TO-901317. Further, gene silencing 
experiments confirmed that abolition of LXR activity significantly affected the resultant 
Hh modulation. In addition to the in vitro activity, reduction of Hh responsive genes by 
TO-901317 was observed in ex vivo as well as in vivo mouse organ cultures. It is 
hypothesized that the pharmacological activity of cholesterol depletion due to LXR 
activation potentially perturbs the post-translational modification of Hh proteins and 
thereby leads to Hh pathway inhibition by TO-901317. 
Another interesting small molecule, norcantharidin (66, Figure 13), was 
developed by researchers in Taiwan as a synthetic derivative of naturally occurring 
molecule, cantharidin. Previously, this compound was known to inhibit drug effux pump 
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protein, P-gp, making it useful against multidrug resistance 127. More recently, it was 
reported to cause reversal of multidrug resistance in human breast cancer cells 
accompanied by downregulation of Shh protein and perturbation of  Gli1 nuclear 
translocation at 10 μM concentration 128. In accordance with its effect on P-gp, 
concomitant treatment of norcantharidin with Doxorubicine (DOX)  also improved 
intracellular accumulation of the latter in MCF7 cells resistant to DOX from 30% to 80%. 
Other noteworthy pharmacological effects of norcantharidin include inhibition of tumor 
angiogenesis by blockade of VEGFR2/MEK/ERK signaling pathways 129.  
Figure 13. Compounds with indirect/unknown/undisclosed mechanism(s) . 
A class of compounds with 2, 4 substituted thiazole was identified in a screen of 
20,000 heterocycles by researchers at The Scripps Research Institute. Within this class, 
JK-184 (67, Figure 13) proved to be nanomolar inhibitor of Gli1 (IC50 30 nM) as 
determined in a Gli dependent luciferase assay. A SAR analysis of this core led to 
optimization of the parent scaffold and guided the discovery of other improved 
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antagonists that have been patented. JK-184 exerts potent antiproliferative effects in a 
panel of cell lines (IC50 values between 3 nM and 21 nM). Preliminary, mechanistic 
characterization suggested that it antagonizes Hh signaling at the level of Gli. 
Additionally, Hh downregulatory effect of this compound is mediated indirectly by 
inhibition of class IV alcohol dehydrogenase 7 [Adh 7] (Kd = 348 nM) 130.Further probing 
revealed other biological effects mediated by this compound such as microtubule 
destabilization to serve as alternate mechanism of action explaining the nanomolar anti-
proliferation potency 131. 
Table 2. Key ‘non-Smo’ Hh pathway inhibitors. 
Cmpd 
IC50 
wild-type Smo
a
 
IC50 
D473H/D477G
a
 
Development 
Status 
Reference 
Robotnikinin 4 µM ND Preclinical 92 
BRD 6851 0.4 µM ND Preclinical 93 
RU-SKI 43 0.85 µM ND Preclinical 91 
GANT-61 5 µM ND Preclinical 96 
NMDA298-1 6.9 µM ND Preclinical 98 
ATO 0.7 µM ~0.8 µM Preclinical 100, 101 
HPI-1 1.5 µM ND Preclinical 103 
NanoHHI active
b
 Active
b
 Preclinical 104 
49a-c 0.5, 19.1, 2 µM  Preclinical 106 
VD3 1-20 µM ND Preclinical 107-110 
53 0.74 µM ND Preclinical 113 
Calcitriol 0.1 µM ND Preclinical 108 
ITZ 0.27-0.69 µM 0.5 µM Phase II 101,116, 117 
58 4 nM ND Preclinical 122 
61-63 38-42 µM NND Preclinical 123 
BRD50837 90 nM ND Preclinical 121 
BRD9526 60 nM ND Preclinical 121 
JK 184 30 nM ND Preclinical 130 
a 
Values assessed using different assay methods described in text
 
b 
Specific IC50 values were not provided 
 
5. Biologics as Hh Pathway Inhibitors 
In addition to the small molecule Hh pathway inhibitors described above, several 
protein-based Hh pathway inhibitors have been described. The best characterized of 
these is 5E1, which was initially generated by scientists at Genentech through mouse 
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hybridoma technology utilizing the N-terminus of rat SHh as the antigen 132. 5E1 inhibits 
pathway signaling by preventing Hh ligands from interacting with Ptch through direct 
binding interactions with the pseudo active site groove of the Hh ligand 133. 5E1 binds 
with high affinity to human SHh and IHh (KD value ranges = 0.13 – 0.31 and 0.16 – 0.29 
nM, respectively) 133, 134. 5E1 also binds to DHh, although at a reduced affinity (KD = 1.7 
nM) 133. The reduced affinity for DHh is likely due to the increased bulk associated with 
Asn179 compared to Ala179 found in the binding epitope of SHh 133. 5E1 is a potent 
inhibitor of Hh signaling in multiple Hh-dependent fibroblast cell lines (IC50 values = 0.33 
– 12.5 nM) 133, 134. 5E1 has also demonstrated the ability to inhibit pathway signaling and 
decrease tumor volume in colorectal xenografts 12, orthotopic and xenograft models of 
pancreatic cancer 135, 136, and medulloblastoma 137, but it has not advanced beyond these 
preclinical studies. 
 A more recent report by researchers at AstraZeneca detailed the development of 
a series of human monoclonal antibodies against SHh as potent pathway inhibitors 134, 
138. Xeno-Mouse mice were immunized against human SHh using both recombinant 
human SHh and KLH-conjugated SHh. Two of the antibodies generated through this 
process, 3H8 and 6D7, were extensively characterized for their SHh-binding and in vitro 
anti-Hh and anti-cancer activity. Interestingly, while both antibodies bound with high 
affinity to human SHh (Kd values = 36 and 5 pM, respectively) only 6D7 bound IHh (Kd = 
34 pM) and neither bound DHh 134. Both antibodies inhibited pathway signaling in Hh-
dependent cell culture (C3H10T1/2) in the low nanomolar range (IC50 values = 3.4 nM 
and 5.3 nM, respectively) 138. Due to its broader substrate specificity, 6D7 was renamed 
MEDI-5304 and further evaluated for its in vivo anti-cancer effects in a compliant model 
(HT-29 human cancer cells and MEFs) of colorectal cancer that mimics paracrine Hh 
signaling 134. MEDI-5304 decreased Hh signaling and tumor volume in this model in a 
 38 
 
dose-dependent fashion (0.1-10 mg/kg); however, the overall reduction in Hh pathway 
target gene expression and tumor growth was modest (~30-50% reduction) 134, 138. In 
addition, preliminary toxicology studies in rats and cynomolgus monkeys did not identify 
adverse effects up to 75 mg/kg.     
6. Conclusion & future directions 
Hh signaling pathway inhibitors are being developed in both academia and 
industry as potential anti-cancer chemotherapeutics. Thus far, pathway inhibitors have 
demonstrated clinical efficacy against cancers in which a specific pathway mutation is 
responsible for tumor formation. However, broader applications against other forms of 
cancer are yet to be fully explored. The initial development of Hh pathway inhibitors 
focused mainly on small molecules antagonists of Smo. In fact, the only pathway 
inhibitor approved by the FDA, Vismodegib, also acts by targeting Smo. Unfortunately, 
multiple mechanisms of resistance to Smo inhibitors have been reported in the recent 
years. Therefore, there is an urgent need to identify and develop novel inhibitors of 
pathway signaling that retain activity against resistant forms of Hh driven tumors. Guided 
by the current progress towards better understanding of structural and functional 
requirements of active molecules, researchers may adopt different strategies to address 
this issue. For instance, several research groups are working to develop pathway 
inhibitors that function downstream of Smo and retain activity against drug resistant Smo 
mutations. Further, the latest characterization of multiple small molecule binding sites on 
Smo can be exploited in the structure-based design of improved Smo antagonists. 
Nonetheless, to present date, advancement of such newer inhibitors beyond preclinical 
and early clinical trials has been nominal. Therefore, there is an immense need for 
continued research in this area. 
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The following chapters describe the progress towards the identification of novel 
small molecule inhibitors of the Hh signaling pathway using a chemical biology-
dependent drug discovery strategy. Since crystal structures of drug binding receptors 
involved in Hh signaling were unavailable prior to 2013, adopting a structure-based drug 
discovery strategy was not feasible when these projects were first started. Alternately, a 
ligand based drug discovery approach was taken to develop Hh inhibitors based on two 
distinct lead structures namely VD3 and ITZ.  
Based on preliminary findings, it was hypothesized that metabolic conversion of 
VD3 to its physiologically active form, calcitriol, can occur in cell culture leading to robust 
activation of VDR signaling. Over activation of VDR signaling results in hypercalcemia, 
hence such off-target effects preclude the clinical use of VD3 as an inhibitor of Hh 
pathway. Therefore, the goals of this project were to pursue a SAR study to identify the 
Hh inhibitory pharmacophore of VD3 and use this knowledge to improve potency and 
selectivity of VD3 based anti-Hh analogues.  
Next, based on a comparative analysis of Hh inhibition mediated by ITZ and 
other marketed azole antifungal drugs that share common structural features interesting 
trends were discovered. This study indicated that integrating structural features of 
Posaconazole (PSZ) with ITZ could potentially lead to superior second generation 
analogues. Thus, the aim for this project was to synthesize and evaluate ITZ derivatives 
with stereochemically defined hydroxylated side chains as mimics of the PSZ side arm.  
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CHAPTER II: Design, Synthesis and Evaluation of Vitamin D3 A-Ring Analogues 
as Hedgehog Pathway Inhibitors 
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1. Introduction 
 
Figure 1. Structure of Vitamin D3 and related compounds.  
A recent study demonstrated that vitamin D3 (VD3), a metabolic precursor to 
1α,25-dihydroxyvitamin D3 [1α,25(OH)2D3, calcitriol], inhibits the Hh signaling pathway 
presumably by binding to Smo (Figure 1) 107. Previous research into the potential 
preventative and therapeutic anti-cancer effects of the vitamin D class of sterols has 
focused on 1α,25(OH)2D3, generally acknowledged as the hormonally active form of 
vitamin D. These anti-cancer effects are primarily mediated through the vitamin D 
receptor (VDR), a nuclear receptor that acts as a transcription factor to regulate 
apoptosis, proliferation, and differentiation 139. The clinical usefulness of 1α,25(OH)2D3 
and analogues has been limited by its tendency to promote hypercalcemia, an effect 
related to its VDR-mediated role in calcium regulation. Another recent publication 
detailing the anti-cancer effects of VD3 in murine models of basal cell carcinoma (BCC) 
suggested that VD3 holds promise as a therapeutic agent in Hh-dependent cancers; 
however, administration of VD3 resulted in significant VDR-mediated cellular effects 110. 
The development of VD3 analogues that exert their anti-cancer effects through 
the Hh pathway inhibition would be less susceptible to hypercalcemic side-effects and 
represent an improved class of vitamin D-based anti-cancer chemotherapeutics. The 
studies described herein represent the first reported SAR studies for VD3 inhibition of Hh 
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signaling. Employing A-Ring analogues with varying 3’ moieties, requirements for 
optimal Hh inhibition and suitability of in vitro assay systems were probed. 
2. Design and synthesis of A-Ring analogues 
2.1 Overview 
 
Scheme 1. Reaction conditions for synthesis of A-Ring analogues. 
As the 3-(S)-hydroxyl of VD3 is the only non-carbon-hydrogen bond in the 
structure, our initial efforts of studying the structure-activity relationships for VD3 
inhibition of Hh signaling began with straightforward modifications at this position  
(Scheme 1). These analogues were designed to probe the optimal configuration and 
hydrogen bonding characteristics at C-3. Standard attempts to oxidize the hydroxyl to 
the corresponding ketone (PDC, Dess-Martin periodinane) proved unsuccessful. 
Conversion to keto VD3 (69) in modest yield was achieved under the more strenuous 
Swern oxidation conditions 140. Standard methylation provided the methoxy-VD3 
derivative (70) in excellent yield. Mesylation of VD3, followed by substitution of the crude 
3-(S)-OMs with sodium azide afforded the 3-(R)-N3 (25% yield over two steps). 
Conversion to the corresponding amine (71) proceeded in modest yield (50%) via 
standard Staudinger reduction conditions 141. The inverted alcohol (72) was generated 
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through Mitsunobu conditions optimized for the VD3 scaffold 142. Subsequent conversion 
of (72) to the 3-(S)-NH2 (73) proceeded in an analogues manner to that described above 
for the inverted amine. 
2.2 Experimental protocols 
(Z)-3-((E)-2-((1R,7aR)-7a-methyl-1-((R)-6-methylheptan-2-yl)hexahydro-1H-inden 
4(2H)-ylidene)ethylidene)-4-methylenecyclohexanone (69). A solution of DMSO (1.85 
mL, 26.0 mmol) in anhydrous CH2Cl2 (12 mL) was added dropwise to a stirred solution 
of oxalyl chloride (1.1 mL, 12.9 mmol) in CH2Cl2 (12 mL) at -78 °C under argon. This 
solution was stirred at -78 °C for 30 min at which time a solution of vitamin D3 (1 g, 2.6 
mmol) in CH2Cl2 (15 mL) was added. This mixture was stirred at -78 °C for 20 min, 
triethylamine (9 mL, 65 mmol) was added, and the mixture was warmed to RT for 30 
min. The mixture was diluted with CH2Cl2 (100 mL) and washed with H2O (100 mL). The 
aqueous layer was removed, the organic layer washed with saturated NaCl (100 mL), 
dried (Na2SO4), and concentrated. Chromatography (SiO2, 3:1, CH2Cl2:Hex) afforded 69 
as a clear oil in moderate yield (33%).1H NMR (CDCl3, 500 MHz) δ 5.95 (s, 1H), 5.43 (s, 
1H), 5.35 (s, 1H), 4.97 (t, J = 7.2 Hz, 1H), 3.18 (t, J = 7.5 Hz, 2H), 2.73 (m, J = 9.6, 5.4 
Hz, 3H), 2.54 (m, J = 14.1, 7.7 Hz, 3H), 2.06 – 1.84 (m, 4H), 1.72 – 1.59 (m, 3H), 1.59 – 
1.42 (m, 5H), 1.42 – 1.23 (m, 8H), 1.23 – 1.09 (m, 4H), 1.09 – 0.98 (m, 2H), 0.94 (d, J = 
6.5 Hz, 3H), 0.89 (dd, J = 6.6, 2.3 Hz, 6H), 0.57 (s, 3H). 13C NMR (CDCl3, 125 MHz) δ 
199.8, 157.9, 142.5, 141.7, 126.7, 115.0, 114.9, 56.5, 55.7, 45.3, 40.4, 39.5, 37.8, 36.2, 
36.1, 32.0, 30.9, 28.7, 28.0, 27.6, 23.9, 23.3, 22.9, 22.6, 22.2, 18.9, 11.9.  IR (film) ʋmax 
2925, 2827, 2378, 1725, 1663, 1450, 1439, 1375, 1258, 1195, 750, 699 cm -1. ESI-
HRMS m/z calculated for C27H44O [M+H]
+ 383.3308, found 383.3314. 
(1S,Z)-3-((E)-2-((1R,7aR)-7a-methyl-1-((R)-6-methylheptan-2-yl)hexahydro-1H 
inden-4(2H)-ylidene)ethylidene)-4-methylenecyclohexanol (70). A solution of vitamin 
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D3 (50 mg, 0.13 mmol) and sodium hydride (4.1 mg, 0.17 mmol) in anhydrous THF (3 
mL) was cooled to 0°C and stirred for 15 min. Methyl iodide (36 mg, 0.26 mmol) was 
added dropwise and the solution warmed to 25°C and stirred for 12 hrs. The solution 
was diluted with EtOAc (10 mL) and washed with H20 (10 mL). The aqueous layer was 
removed, the organic layer washed with saturated NaCl (10 mL), dried (Na2SO4), and 
concentrated. Chromatography (SiO2, 20:1, Hex:EtOAc) afforded 70 as a clear oil in 
excellent yield (82%). 1H NMR (CDCl3, 500 MHz) δ 6.25 (d, J = 11.2 Hz, 1H), 6.06 (d, J 
= 11.2 Hz, 1H), 5.06 (s, 1H), 4.84 (s, 1H), 3.43 (m, 1H), 3.37 (s, 3H), 2.90 – 2.81 (m, 
1H), 2.60 (d, J = 13.1, 1H), 2.47 – 2.38 (m, 1H), 2.31 (m, 1H), 2.19 – 2.10 (m, 1H), 2.05 
– 0.99 (m, 24H), 0.89 (dd, J = 6.6, 2.2 Hz, 6H), 0.58 (s, 3H). 13C NMR (CDCl3, 125 
MHz) δ 145.3, 141.7, 135.5, 121.8, 117.7, 112.2, 78.0, 56.6, 56.3, 55.8, 45.7, 42.4, 40.5, 
39.4, 36.1 (2H), 32.2, 31.9, 28.0, 27.0, 27.6, 23.8, 23.5, 22.8, 22.5, 22.2, 18.8, 12.0. IR 
(film) ʋmax 3007, 2950, 2847, 1722, 1467, 1442, 1388, 1255, 1098, 748, 699 cm
-1. ESI-
HRMS m/z calculated for C28H47O [M+H]
+ 399.3621, found 399.3646. 
General synthetic procedure for generating 71 and 73. The general synthesis 
of 71 and 73 followed a slight modification of the previously published procedure 141. A 
solution of vitamin D3 (1 g, 2.6 mmol) and triethylamine (1 g, 10.4 mmol) in CH2Cl2 (15 
mL) was cooled to 0°C and stirred for 5 mins. Methanesulfonyl chloride (595 mg, 5.2 
mmol) was added dropwise and the solution warmed to 25°C over 20 min. The CH2Cl2 
was removed and the mixture redissolved in EtOAc (10 mL) and saturated sodium 
bicarbonate (10 mL). The aqueous layer was removed, the organic layer was washed 
with H20 (10 mL) and saturated NaCl (10 mL). The organic layer was  dried (Na2SO4) and 
concentrated. The resulting crude mesylate (1 g, 2.2 mmol) and sodium azide  (1.43 g, 
22 mmol) in anhydrous DMF (15 mL) was stirred at 60°C for 12 hr. The mixture was  
diluted with EtOAc (50 mL) and H2O (50 mL). The aqueous layer was removed, the 
organic layer washed with saturated NaCl (10 mL), dried (Na2SO4), and concentrated. 
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Chromatography (SiO2, 1: 1, CH2Cl2: EtOAc) afforded the inverted azides as a yellow oil 
in modest yield (25% over two steps). Azide (100 mg, 0.24 mmol), triphenylphosphine 
(128 mg, 4.9 mmol), and H2O (43 μL, 2.4 mmol) were stirred in THF (10 mL) under 
positive argon pressure at RT for 12 hr. The solution was concentrated and 
chromatography (SiO2, 20:1:0.1, CH2Cl2: MeOH, NH4OH) afforded the previously 
described amines as a yellow oil in modest yield (50%). 
3. Biological evaluation 
3.1 Experimental protocols  
RT-PCR protocol: Following treatment and incubation, RNA was extracted with 
TRIZOL® Reagent following the manufacturer’s instructions. cDNA synthesis was 
performed utilizing the High Capacity cDNA Reverse Transcription Kit (ABI) per the 
manufacturer’s instructions on a BioRad MyCycler. Quantitative RT -PCR was performed 
on an ABI 7500 system using the following Taqman Gene Expression Assays: human 
GLI1, Hs00171790_m1; human Cyp24A1, Hs00167999_m1; human ActB, 
Hs99999903_ml; mouse GLI1, Mm00494645_m1; mouse Cyp24A1, Mm00487244_m1; 
mouse ActB, Mm00607939_s1. Relative gene expression levels were computed via the 
ΔΔCt method using GraphPad Prism.      
Anti-proliferation protocol: Cells (3000/well, 100 µL) were seeded in 96-well 
plates and incubated overnight (37°C, 5% CO2). Cells were treated in triplicate with 
DMSO, VD3, Cyc, or analogue at varying concentrations (1% DMSO final 
concentration). Following 72-hr incubation, viable cells were measured using CellTiter 
96® aqueous Non-Radioactive Cell Proliferation Assay (Promega) per the manufacturer’s 
instructions. Data was analyzed using GraphPad Prism and IC50 values represent mean 
± SEM for at least three separate experiments. 
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3.2 Results & discussion 
The Hh inhibitory activity of VD3 and 69-73 was initially examined through down-
regulation of endogenous Gli1 mRNA in the Hh–dependent C3H10T1/2 cell line 46. In 
this well-studied model system, the Hh pathway is silent under normal growth conditions 
and Gli1 expression is negligible. Incubation with oxysterols [20(S)- and 22(S)-
hydroxycholesterol, 5 µM each] activates the pathway and results in significant 
(approximately 100-fold) up-regulation of Gli1 while co-administration with Hh pathway 
inhibitors prevents Gli1 up-regulation. For these studies, VD3 and 69-73 were evaluated 
at 5 µM and Gli1 mRNA expression levels were normalized to oxysterol controls (set as 
100% expression). Several interesting SAR were observed from these assays (Table 1). 
First, removal of the hydrogen in analogues 69 and 70 resulted in a moderate to 
significant decrease in Hh inhibitory activity. In addition, both amine epimers, 71 and 73, 
were 2-fold less active than VD3. Finally, inverting the stereochemistry at C-3 did not 
have an appreciable effect on Hh inhibition, suggesting the S-configuration of natural 
VD3 is not required for activity.  
Table 1. In vitro activity of VD3 A-ring analogues. 
Analogue 3-moiety Relative Gli1 mRNA (%)
a
 
Anti-proliferation 
IC50 (µM)
b
 
VDR 
Binding 
Cyc ---- 6.93 ±1.93 22.5 ± 0.5 ---- 
VD3 3-(S)-OH 31.7 ± 0.7 29.7 ± 3.1 >100µM 
69 3-keto 50.1 ± 6.4 50.6 ± 1.8 >100µM 
70 3-(S)-OMe 72.2 ± 11 54.2 ± 6.2 >100µM 
71 3-(R)-NH2 68.0 ± 7.0 12.3 ± 0.5 >100µM 
72 3-(R)-OH 25.0 ± 6.0 39.2 ± 1.5 >100µM 
73 3-(S)-NH2 62.7 ± 2.7 12.3 ± 0.1 >100µM 
a
Relative Gli1 mRNA levels in C3H10T1/2 w hen oxysterol treatment is equivalent to 100%. 
b
IC50 values measured in U87MG cells (MTS assay). 
In addition to evaluating the Hh inhibitory activity of VD3 and analogues, we 
sought to measure their anti-proliferative activities in human cancer cells. Recent studies 
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have suggested that the in vivo tumor microenvironment is required for proper Hh 
signaling and that cultured cancer cells may not function as an appropriate model 
system 12. Nevertheless, Cyc treatment was previously shown to result in Gli1 down-
regulation in the human glioblastoma cell line U87MG; therefore, we evaluated VD3 and 
analogues in this cellular model 143. Interestingly, the two most active analogues in this 
assay were 71 and 73, the 3-(R)- and 3-(S)-amines (IC50s = 12.3 ± 0.1 and 12.3 ± 0.1, 
respectively). These results were in direct contrast with the Hh inhibitory activity of these 
compounds. The other compounds demonstrated modest anti-proliferation with IC50 
values approximately 3-fold higher than 71 and 73.  
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Figure 2. Relative  Gli1 mRNA expression in U87MG cells.  
(A) 5 µM treatment at 24 hr (B) Time-dependent Gli1 regulation with 10 µM compound.   
The further analysis of VD3 and analogues included evaluating their ability to 
down-regulate Gli1 in U87MG cells. At 5 µM, none of the compounds evaluated 
significantly down-regulated Gli1 expression after 24 hrs (Figure 2A). As previous 
studies that demonstrated Cyc inhibits Hh signaling in U87MG cells measured Gli1 
down-regulation following 4 hr incubation at 10 µM of the natural product, we evaluated 
each Hh inhibitor at this increased concentration and varying time points (Figure 2B)  143. 
Under these conditions, none of the compounds tested demonstrated significant Gli1 
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down-regulation in this cell line. In fact, Cyc treatment resulted in a slight increase in Gli1 
expression levels at 8 hr.  
Based on these conflicting results and our ultimate goal of developing VD3 
analogues that specifically target Smo and the Hh pathway, we evaluated each 
compound for its ability to regulate VDR signaling. VD3 and analogues were explored for 
their ability to bind VDR. For this assay, we utilized the PolarScreen™ VDR Competitor 
Assay, Red (Invitrogen) per the manufacturer’s instructions. This assay is a fluorescence 
polarization-based competition assay that has been optimized for high-throughput 
applications and contains all the required components (including full length human VDR 
and a proprietary tight-binding fluorescent VDR ligand).  Neither VD3 nor the A-ring 
analogues exhibited VDR binding at concentrations up to 100 µM, suggesting these 
compounds do not exhibit their biological activity through direct binding interactions with 
VDR (Table 1).  
 
 Figure 3. Vitamin D metabolic pathway. 
Our next step towards understanding the cellular mechanisms responsible for the 
anti-proliferative activity of VD3 and 69-73 in U87MG cells was to evaluate their ability to 
activate VDR in cell culture. Primarily, VD3 is metabolized in liver and kidney by various 
Cyp450 enzymes to yield 25(OH)D3 and 1α,25(OH)2D3 (Figure 3), forms of vitamin D 
which bind and activate VDR. Recent evidence has shown that various types of human 
cancers express increased levels of these metabolic enzymes 144-147. While it remains 
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unclear whether the over-expression of these enzymes plays a role in the proliferation of 
human cancers, their presence outside the liver and kidney suggests that the possible 
metabolic transformation of VD3 and analogues in cancer cells may result in structures 
which activate VDR signaling 148. With respect to VDR regulation, Cyp24A1 is 
responsible for converting 1α,25(OH)2D3  into the physiologically inactive calcitroic acid. 
Cyp24A1 is elevated in response to VDR activation and serves as a natural feedback 
mechanism to regulate VDR signaling. For this reason, induction of Cyp24A1 is 
commonly used to monitor cellular activation of the VDR signaling. Incubation of U87MG 
cells with VD3 resulted in significant up-regulation of Cyp24A1 (~5-fold, Table 2). In 
addition, the VD3-epimer 72 demonstrated Cyp24A1 up-regulation comparable to VD3. 
Each amine exhibited modest VDR activation, while neither keto- nor methoxy-VD3 had 
a significant effect. In order to determine whether these effects were cell type 
dependent, we explored Cyp24A1 up-regulation in HT-29 cells, a colon cancer cell line 
known to produce a robust and reproducible Cyp24A1 response to 1α,25(OH)2D3 
administration 149, 150. VD3, 1α,25(OH)2D3 (0.1 µM), and 72 demonstrated significant up-
regulation of Cyp24A1 in HT-29 cells. A recent study reported a modest increase in 
Cyp27A1 and Cyp27B1 expression upon administration of VD3 in HT-29 cells 151. In this 
same study, significant up-regulation of Cyp24A1 following VD3 treatment was delayed 
compared to 1α,25(OH)2D3  (24 hr and 4 hr, respectively), suggesting cellular 
conversion of VD3 to a more active form is necessary for VDR activation. By contrast, 
Cyc had no effects on Cyp24A1 in either cell line, confirming this effect as specific to the 
VD3 scaffold and not a general response related to Hh inhibition. Finally, we studied the 
ability of each compound to up-regulate Cyp24A1 in the C3H10T1/2 cell model. Similar 
to the results obtained in HT-29 cells, both VD3 and 72 resulted in significant Cyp24A1 
up-regulation (Table 2). Of note, these results do not explain the anti-cancer activity for 
amines 71 and 73. These two analogues were the most active in the anti-proliferative 
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assays; however, they are poor inhibitors of Hh signaling and do not activate VDR in 
cultured cells, suggesting their activity may be mediated by an as yet unidentified ce llular 
signaling mechanism.      
Table 2. Up-regulation of Cyp24A1 mRNA expression by VD3 and analogues. 
Analogue
a
 U87MG HT-29 C3H10T1/2 
Cyc 1.6 ± 0.1
b
 0.9 ± 0.1 0.99 ± 0.1 
VD3 4.9 ± 1.1 1063 ± 83 5786 ± 190 
69 1.3 ± 0.02 0.9 ± 0.1 130 ± 33 
70 1.0 ± 0.1 4.2 ± 0.1 1.1 ± 0.1 
71 3.3 ± 0.4 6.1 ± 0.2 6.3 ± 2.2 
72 6.9 ± 1.2 1654 ± 48 1444 ± 241 
73 3.5 ± 0.3 6.4 ± 0.1 13.0 ± 3.6 
1α,25(OH)2D3 ---- 14160 ± 691 27890 ± 2774 
a
All compounds except 1α,25(OH)2D3 (0.1 µM) evaluated at 5 µM in C3H10T1/2 & 10 µM in HT-29 & 
U87MG  
b
Values represent Cyp24A1 mRNA expression level in cultured cells w hen DMSO set as 1.0.  
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Figure 4. Relative Cyp24A1 mRNA levels in C3H10T1/2 cells. 
VD3 (A), 25(OH)D3 (B), and 1α,25(OH)2D3 (C) treatment (24hr).  
DMSO w as set as 1.0 and mRNA expression levels for treatments w ere calculated accordingly [p<0.0001]. 
 51 
 
The data for VD3 supports our hypothesis that its metabolism in cultured cancer 
cells results in a form that more readily activates VDR; however, these results also 
provide another source of potential confusion regarding VDR/Hh signaling. Recent 
studies exploring the relationships between VDR signaling and the Hh pathway have 
suggested that 1α,25(OH)2D3 may directly regulate Hh signaling 
152. It is unclear 
whether these modulatory effects are mediated through direct inhibition of Hh signaling 
or as a downstream effect of VDR activation. In addition, minimal studies detailing the 
effects of 1α,25(OH)2D3 in C3H10T1/2 cells have been reported. For these reasons, we 
sought to evaluate the dose-dependent effects on Hh and VDR signaling of VD3, 
25(OH)2D3 and 1α,25(OH)2D3 in this cell line (Figure 4). Not surprisingly, each vitamin D 
compound significantly up-regulated Cyp24A1 in a dose-dependent fashion. Of note, the 
lowest concentration of VD3 evaluated (0.5 µM) did not activate VDR signaling, while 
both 25(OH)2D3 and 1α,25(OH)2D3 maintained robust Cyp24A1 up-regulation; lending 
further support to the hypothesis that these VD3 metabolites, and not VD3 itself, mediate 
the VDR response seen upon VD3 administration. In addition, both 25(OH) 2D3 and 
1α,25(OH)2D3 significantly reduced GLI1 expression levels in this cell line. 
  4. Conclusion 
Taken together, these results provide a better understanding of the necessary 
requirements for developing VD3 analogues as selective Hh pathway inhibitors. First, 
not only can VD3 analogues not directly interact with VDR, modifications to the scaffold 
must also yield structures that are not substrates for Cyp27A1 and Cyp2R1, enzymes 
that catalyze the metabolism of VD3 to 25(OH)2D3. Second, while both 25(OH)2D3 and 
1α,25(OH)2D3 inhibit Hh signaling, they produce a robust VDR response in multiple cell 
lines and do not represent selective scaffolds for the development of Hh pathway 
inhibitors. Finally, as described above, there is no correlation between Hh inhibition in 
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C3H10T1/2 cells and Gli1 down-regulation in cultured epithelial cancer cells, supporting 
the recent findings that the in vivo tumor microenvironment is required for proper Hh 
signaling in human cancer.  
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CHAPTER III: Design, Synthesis and Evaluation of Hybrid Vitamin D3 Side Chain 
Analogues as Hedgehog Pathway Inhibitors 
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1. Introduction 
Previous studies undertaken in our lab revealed that VD3 mediated inhibition of 
Hh signaling in vitro is modest (IC50 = 4.1μM) and non-selective due to its ability to 
concurrently activate canonical VDR signaling 108, 113. Thereafter, a medicinal chemistry 
approach was undertaken to design analogues of VD3 that selectively target Hh 
signaling. Initial attempts with analogues prepared by simple modifications of the 3’-
hydroxyl functionality of the A-ring proved inadequate 108. Next, as a part of our ongoing 
SAR studies to elucidate the pharmacophore of VD3 necessary for selective inhibition of 
Hh signaling, we adopted a deconstructive approach of studying analogues arising from 
each region of VD3 (Figure 1) 111.  The key observations of this study were that the 
truncated side chain analogues of VD3, 74, Inhoffen Lythgoe diol, 75, along with the 
‘southern’ fragment of VD3, 76, showed a considerable loss of activity. However, 
analogues with intact ‘northern’ regions of VD3 and VD2, 77 and 78, retained Hh 
inhibitory activity comparable to VD3 albeit in a more selective fashion (Table 1). 
Therefore, probing the structural requirements of the CD-ring side chain region was the 
next warranted step. Studies described in this chapter were aimed at unraveling the 
optimum requirements for length and nature of VD3 side chain for potent and selective 
Hh inhibitory activity. 
 
Figure 1. Structures of truncated VD3 analogues. 
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Table 1. Gli1 inhibitory activity and selectivity of truncated VD3 analogues.  
Analogue Relative Gli1 mRNA (%)
a
 Relative Cyp24A1 mRNA
b
 
VD3 35.7 ± 0.3 8336 ± 38 
74 80.0 ± 10.4 1354 ± 61 
75 87.6 ± 1.2 4.1 ± 0.7 
76 46.4 ±3.5 3.6 ± 0.5 
77 80.9 ± 2.1 2.0 ± 0.2 
78 32.1 ± 6.3 2.3 ± 1.2 
a
Relative Gli1 mRNA levels in C3H10T1/2 w hen oxysterol treatment is equivalent to 100%. 
b
Values represent Cyp24A1 mRNA expression in cultured cells relative to DMSO (1.0). 
Initial attempts to prepare side chain derivatives proceeded with sulfur dioxide 
protection of the VD2 triene and protection of the 3’ hydroxyl group as the silyl ether, 
followed by selective ozonolysis/reduction of the side chain olefin to provide T ES-
protected trans-VD3 alcohol 82 (Scheme 1) 153. The next steps included tosylation of the 
resultant primary hydroxyl group and removal of the triene protecting group yie lding the 
trans-VD3 derivative 84 153, 154. Subsequent photoisomerism led to precursor 85 required 
for the alkylation reaction via displacement of the primary tosylate using various 
commercially available Grignard reagents 153, 155. Finally deprotection of the 3’-hydroxyl 
group afforded analogues with modified side chains 86. This initial scheme to prepare 
VD3 analogues with side chain modifications proved challenging as several attempts to 
displace the tosyl functionality using a Grignard’s reagent either failed or proceeded in 
extremely low yields (0% - 5%).  Additionally, the inherent instability of the conjugated 
triene system of VD3 in solution due to thermal equilibrium between VD3 and pre -VD3 
via a [1, 7]-sigmatropic hydrogen shift, posed general complications during synthetic 
manipulations of this structure 156. Further biological evaluation of analogue 86 could not 
be carried out due to lack of necessary amounts of pure product required for complete 
chemical characterization and sample preparation for dosing cells.  
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Scheme 1. Synthetic route to VD3 side chain analogues.  
In concurrent studies, the ‘northern’ region of VD3, also known as Grundmann’s 
alcohol (77), was found to be equipotent to the parent VD3 scaffold (IC50 values = 3.1 
and 4.1 µM respectively) 111, 113. Based on this finding, subsequent series of VD3 
analogues designed to incorporate an aromatic A-ring isostere that maintains the 
approximate steric and hydrophobic features of the natural aliphatic A-ring into the seco-
steroid scaffold identified compound 87 as a selective Hh inhibitor with enhanced activity 
(IC50 = 0.74 µM) (Figure 2) 
113.   Following the identification of improved Hh inhibitory 
scaffold 87, we directed our efforts to incorporate the side chain modifications on this 
revised core structure. With this revision in design strategy, we aimed to fulfill analogue 
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optimization for enhanced potency and selectivity along with affording relative efficiency 
and ease in accessing hybrid side chain analogues.   
 
Figure 2. Development of hybrid VD3 as selective and potent Hh inhibitor. 
2. Synthesis of hybrid side chain analogues of VD3 
2.1 Overview 
2.1.1 Route 1 
Complete ozonolysis of VD2 and subsequent reduction of the resultant ozonide 
in a one-pot reaction generated the previously characterized Inhoffen Lythgoe diol, 75 
(Scheme 2) 157.  The next step of preferential tosylation of the primary hydroxyl group in 
presence of another slightly hindered secondary hydroxyl group proceeded with modest 
yields leading to the preparation of key CD ring intermediate (88, Scheme 2) 158. For the 
synthesis of the Ring-A aromatic mimic two consecutive protection/deprotection steps 
were carried out to prepare the carboxylate intermediate (91, Scheme 2) 159, 160. With the 
necessary precursors in hand, the next step of esterification to prepare intermediate (92) 
proceeded with modest yields (Scheme 3) 113. Syntheses of two linear (93, 94), one 
branched alkyl (95) and one aromatic (96) side chain derivative were accomplished via 
displacement of the tosyl functional group from intermediate (92) using appropriate alkyl 
nucleophiles followed by a final deprotection step (Scheme 3). However, it became 
necessary to determine an alternate method due to the low yields and inconsistent 
reproducibility of the tosyl displacement step. Therefore, we sought to identify a viable 
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route to prepare additional analogues in an efficient manner using the current building 
blocks and available infrastructure.   
 
Scheme 2. Route 1: Synthesis of CD-ring and A-ring precursor. 
 
Scheme 3. Route 1: Preparation of hybrid side chain analogues. 
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2.1.2 Route 2 
In this alternate route (Scheme 4), displacement of the tosyl moiety by relevant 
alkyl nucleophiles was carried out on intermediate (88) prior to the esterification step 155. 
After installation of the necessary side chains on the CD-ring fragment to generate 
intermediate (97), previously described methods for esterification with intermediate (91) 
and unmasking of the 3’ hydroxyl group of the aromatic A-ring mimic were carried out 
with improved yields.  In this manner, a total of seven additional linear as well as 
branched alkyl chain analogues (98 – 104) were synthesized. 
 
Scheme 4. Route 2: Preparation of hybrid side chain analogues.  
2.1.3 Route 3 
The preparation of additional hybrid VD3 side chain analogues was undertaken 
by adopting relevant modifications of the previously described routes. For instance, 
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naturally occurring unsaturated side chain precursor (78) was obtained from VD2 by 
oxidative cleavage of the VD2 triol (Scheme 5) 111. By varying the nature of protecting 
groups used for masking A-ring phenolic moiety and hence the subsequent deprotection 
reactions required, two derivatives containing VD2-like side chains were accessible from 
78 (Scheme 6). First, employing benzyl protected intermediate 106 in the esterification 
reaction followed by global deprotection and reduction afforded analogue 109 with 
relative ease. Alternately, coupling to A-ring mimic precursor 91 containing the 
methoxymethyl functionality led to the preparation of analogue 111 with an unsaturated 
side chain. Next, utilizing trimethylsilyl ether to mask the primary hydroxyl moiety of the 
Inhoffen Lythgoe diol, intermediate 107 was synthesized in the presence of a catalytic 
amount of DMAP 161. Esterification of this intermediate succeeded by one-step removal 
of both protecting functional groups produced non-hydrocarbon side chain containing 
analogue 113 (Scheme 5 and 6).  
 
Scheme 5. Route 3: synthesis of CD-ring and A-ring precursor. 
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Scheme 6. Route 3: Access additional hybrid side chain analogues. 
2.1.4 Synthetic strategy 
The displacement of the tosyl functional group with a carbon based nucleophile 
obtained from relevant Grignard reagents represents the key transformation leading to 
the installation of various side arms on the hybrid VD3 scaffold.  Initial attempts to carry 
out this reaction on relatively bulkier molecules such as intermediate 85 (Scheme 1) or 
intermediate 92 (Scheme 3) proved inadequate and inefficient. Not only were the 
reaction yields extremely poor (5%-10%), the reactions rarely proceeded to completion. 
Furthermore, methodical investigation of the effects of altering reaction parameters 
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including reaction time, temperature, solvent and copper catalyst did not offer 
reasonable improvement. 
 
Figure 3. Comparison of intermediate structures during Ts displacement reaction. 
Thereafter, the synthetic strategy was modified based on the hypothesis that less 
bulky substrates may facilitate effective completion of the rate determining step of 
complex formation with the copper catalyst (Figure 3). Guided by a previous literature 
report detailing successful displacement of the tosyl moiety from tosylated Inhofen 
Lythgoe diol 88 with Grignard reagents, a revised strategy (Route 2, Scheme 4) was 
adopted 162. Although this shift in strategy lengthened the synthetic route to access the 
analogues, it afforded reaction reproducibility and improved yields.  
2.2 Experimental protocols 
  Preparation of tosylated MOM-ester (92): Tosylated Inhoffen Lythgoe diol (88) 
(0.2 g, 0.55 mmol), dicyclohexylcarbodiimide (0.34 g, 1.65 mmol), and 
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dimethylaminopyridine (0.2 g, 1.64 mmol) were dissolved in anhydrous CH2Cl2 (6-8 ml) 
in an oven-dried round bottom flask. Carboxylic acid (91) (0.3 g, 1.65 mmol) was added 
at 0o C, the reaction mixture was allowed to warm to RT and stirred for 12 h. The 
reaction mixture was diluted with CH2Cl2 (30 ml), washed with 0.1N HCl and brine, dried 
over Na2SO4 and concentrated under reduced pressure. The crude mixture was purif ied 
using column chromatography (SiO2, 5-25% EtOAc in hexanes) to yield product as clear 
oil in 40% yield. 
General procedure for Tosyl group displacement: Commercially purchased 
Grignard reagents (5 eq.) were added to an oven-dried round bottom flask containing 
CuI (1.6 eq.) in anhydrous THF (3-5 ml) under argon and stirred for 0.5 h at 0oC. (85) (1 
eq.) or (92) (1 eq.) or (88) (1 eq.) dissolved in anhydrous THF (1 ml) was added to the 
reaction mixture and stirred for 1 h at 0oC. The reaction was quenched by addition of 
water, extracted with EtOAc (3X), washed with 0.1N HCl (3X), dried over Na 2SO4 and 
concentrated under reduced pressure. The crude mixture was purified using column 
chromatography (SiO2, 0-20% EtOAc in hexanes) to yield products as clear oils in 10-
40% yield. 
General procedure for removal of methoxymethyl (MOM) protecting group: 
To a solution of MOM-protected ester intermediate (20-25 mg, 1 eq.) in DCM (2 ml), 
excess of trifluoroacetic acid (10 eq.) was added. The reaction mixture was stirred a t RT 
and reaction progress was monitored by thin layer chromatography. Upon completion, 
the reaction was neutralized using saturated Na2CO3 and washed with DCM. The 
combined organic layer was dried over Na2SO4, concentrated under reduced pressure 
and purified using column chromatography (SiO2, 0-15% EtOAc in hexanes) to yield 
products as clear oils in 65% yield. 
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General procedure for esterification: (97), (78), or (107) (1 eq.), 
dicyclohexylcarbodiimide (3 eq.), and dimethylaminopyridine (3 eq.) were dissolved in 
anhydrous DCM (2-4 ml) in an oven-dried round bottom flask. Carboxylic acid (91) (3 
eq.) dissolved in DCM was added at 0oC, the reaction mixture was allowed to warm to 
RT and stirred for 12 h. The reaction mixture was diluted with DCM (3x), washed with 
0.1N HCl and brine, dried over Na2SO4 and concentrated under reduced pressure. The 
crude mixture was purified using column chromatography (SiO2, 5-25% EtOAc in 
hexanes) to yield products as clear oils in 50-70% yield. 
Preparation of benzyl protected methyl ester (105): To a stirred solution of 3-
phenolic methyl ester 89 (1eq., 6.5 mmol) in acetone (30 mL), was added potassium 
carbonate (anhydrous, 6 eq., 39 mmoL) followed by benzyl bromide (1.2 eq., 7.9 mmol). 
The reaction mixture was refluxed until methyl ester was consumed (6h). The mixture 
was filtered over a celite pad, washed with EtOAC (30 mL), and concentrated. The crude 
residue was purified by column chromatography on silica gel (5% EtOAC in hexanes) to 
afford pure product as a clear oil in excellent yield (85%). 
Preparation of benzyl protected 3’ hydroxybenzoic acid (106): To a stirred 
solution of ester (105) (3.7 mmol) in THF (30 mL) was added potassium hydroxide (aq., 
20%; 20 mL). The reaction mixture was stirred at room temperature for 12 hr at which 
time it was neutralized with portion-wise additions of 3N HCl and then the pH was 
reduced to ~1 using 1N HCl. The aqueous mixture was washed with EtOAc (3X100 mL). 
The combined organic fractions were dried (Na2SO4), filtered, and concentrated under 
reduced pressure. The crude residue was purified by column chromatography on silica 
gel (30-50% EtOAC in hexanes) to afford pure productas a white solid in good yield 
(70%).  
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Preparation of analogue 109: To a solution of benzyl-protected ester 108 (0.15 
mmoL) in MeOH:THF (2:1, 6 mL) was added palladium hydroxide (10% on carbon; 10 
mg). The mixture was sealed with a rubber septum, sequentially purged with argon and 
hydrogen, and stirred under positive hydrogen pressure (1 atm) at RT for 18 h. The 
mixture was filtered through a Celite pad, rinsed with EtOAC (10 mL) and concentrated 
under reduced pressure. The crude residue was purified using column chromatography 
(SiO2, 10−40% EtOAc in hexanes) to yield 109 in 75% yield. 
Preparation of TMS protected Inhoffen Lythgoe diol (107): To a solution of 
Inhoffen Lythgoe diol 75 (0.2 g, 0.9 mmol)  in anhydrous DCM (10 ml), triethylamine 
(0.15 ml, 1.1 mmol), dimethylaminopyridine (0.004 g, 0.04 mmol)  and TMSCl (0.127 ml, 
0.99 mmol)  were added and stirred overnight. The reaction mixture was diluted with 
DCM, washed with water, dried over Na2SO4 and concentrated under reduced pressure. 
Purification using column chromatography (SiO2, EtOAc in hexanes) yielded pure 
product as clear oil in 49% yield. 
 (1R,3aR,4S,7aR)-1-isopropyl-7a-methyloctahydro-1H-inden-4-yl 3-hydroxybenzoa-
te (93): 1H NMR (500 MHz, CDCl3) δ 7.65 (m, J = 7.8, 1.2 Hz, 1H), 7.58 (m, J = 2.6, 1.2 
Hz, 1H), 7.35 (m, J = 7.9, 2.2 Hz, 1H), 7.07 (m, J = 8.1, 2.4, 1.0 Hz, 1H), 5.42 (m, J = 2.7 
Hz, 1H), 5.36 (s, 1H), 2.13 – 2.04 (m, 2H), 2.01 (dd, J = 14.5, 3.8 Hz, 1H), 1.84 (m, J = 
21.5, 18.5, 9.3, 5.3 Hz, 3H), 1.56 (m, J = 20.7, 14.0, 10.9, 7.3, 3.6 Hz, 7H), 1.50 – 1.38 
(m, 1H), 1.36 – 1.30 (m, 1H), 1.26 – 1.18 (m, 1H), 1.06 (d, J = 2.2 Hz, 4H), 0.98 (dd, J = 
6.5, 2.2 Hz, 3H), 0.88 (dd, J = 6.6, 2.2 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 166.5, 
155.8, 132.4, 129.7, 122.0, 119.9, 116.3, 72.6, 58.5, 51.6, 41.9, 39.8, 30.7, 30.5, 29.7, 
27.3, 23.0, 22.7, 22.4, 18.0, 13.7. IR (film) ʋmax 3430 (br s), 2956, 2939, 2868, 2858, 
1700, 1684, 1601, 1589, 1294, 1217, 1160, 1110, 946, 756, 680, 669. DART -HRMS: 
m/z calculated for C20H28O3NH4: 334.2382 [M+NH4]
+. Found: 334.2373. 
 66 
 
 (1R,3aR,4S,7aR)-7a-methyl-1-((R)-pentan-2-yl)octahydro-1H-inden-4-yl 3-hydroxy-
benzoate (94): 1H NMR (500 MHz, CDCl3) δ 7.65 (m, J = 7.6, 2.9, 1.5 Hz, 1H), 7.59 (p, J 
= 1.9 Hz, 1H), 7.34 (m, J = 7.9, 2.0 Hz, 1H), 7.11 – 7.05 (m, 1H), 5.51 (s, 1H), 5.45 – 
5.40 (m, 1H), 2.13 – 2.06 (m, 1H), 1.92 – 1.77 (m, 2H), 2.01 (m, J = 12.9, 5.1, 2.7 Hz, 
1H), 1.69 – 1.50 (m, 5H), 1.50 – 1.34 (m, 3H), 1.29 (t, J = 2.3 Hz, 3H), 1.21 – 1.11 (m, 
1H), 1.06 (p, J = 2.7 Hz, 4H), 0.95 (m, J = 6.5, 2.1 Hz, 3H), 0.93 – 0.87 (m, 3H). 13C 
NMR (126 MHz, CDCl3) δ 166.6, 155.9, 132.5, 129.8, 122.1, 120.1, 116.5, 72.8, 56.7, 
51.8, 42.1, 40.1, 38.3, 35.4, 30.7, 29.9, 27.3, 22.9, 19.4, 18.8, 18.2, 13.8. IR (film) ʋ max 
3400 (br s), 2976, 2947, 2867, 2866, 1684, 1600, 1579, 1296, 1215, 1145, 1110, 946, 
756, 680, 659. DART-HRMS: m/z calculated for C22H32O3NH4: 362.2695 [M+NH4]
+. 
Found: 362.2714. 
(1R,3aR,4S,7aR)-7a-methyl-1-((R)-5-methylhexan-2-yl)octahydro-1H-inden-4-yl 3-
hydroxybenzoate (95): 1H NMR (500 MHz, CDCl3) δ 7.65 (d, J = 7.5 Hz, 1H), 7.59 (d, J 
= 6.8 Hz, 1H), 7.35 (t, J = 8.0 Hz, 1H), 7.13 – 7.03 (m, 1H), 5.42 (m, J = 4.1, 2.2 Hz, 1H), 
2.08 (m, J = 11.3, 3.9 Hz, 1H), 2.05 – 1.97 (m, 1H), 1.93 – 1.71 (m, 2H), 1.56 (m, J = 
18.9, 12.5, 8.9, 4.5 Hz, 4H), 1.49 – 1.30 (m, 6H), 1.28 – 1.09 (m, 4H), 1.05 (s, 3H), 0.96 
(d, J = 13.2, 6.2 Hz, 3H), 0.91 (dd, J = 6.6, 1.9 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 
166.3, 155.7, 132.4, 129.7, 122.0, 119.9, 116.3, 72.6, 58.5, 51.6, 41.9, 39.8, 35.5, 31.9, 
30.9, 30.7, 30.5, 29.7, 27.3, 23.0, 22.7, 22.4, 18.0, 13.7. IR (film) ʋ max 3385 (br s), 3019, 
2951, 2935, 2868, 1689, 1599, 1589, 1466, 1453, 1366, 1344, 1295, 1215, 1157, 1106, 
1075, 1062, 982, 946, 886, 755, 680, 668. DART-HRMS: m/z calculated for 
C24H36O3NH4: 391.2848 [M+NH4]
+. Found: 391.2869.  
(1R,3aR,4S,7aR)-7a-methyl-1-((R)-4-phenylbutan-2-yl)octahydro-1H-inden-4-
yl 3-hydroxybenzoate (96): 1H NMR (500 MHz, CDCl3) δ 7.64 (d, J = 7.6 Hz, 1H), 
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7.60 – 7.57 (m, 1H), 7.33 (dd, J = 21.9, 7.9 Hz, 3H), 7.22 – 7.17 (m, 3H), 7.08 (dd, J = 
8.1, 2.6 Hz, 1H), 5.57 (s, 1H), 5.42 (q, J = 2.7 Hz, 1H), 2.73 (m, J = 13.2, 11.2, 4.8 Hz, 
1H), 2.50 (m, J = 13.4, 10.8, 6.0 Hz, 1H), 2.11 (m, J = 12.7, 3.5 Hz, 1H), 2.02 (m, J = 
14.1, 2.5 Hz, 1H), 1.96 – 1.71 (m, 4H), 1.67 (q, J = 4.1 Hz, 1H), 1.64 – 1.45 (m, 4H), 
1.44 – 1.33 (m, 1H), 1.29 (s, 2H), 1.24 (d, J = 7.3 Hz, 1H), 1.07 (d, J = 6.6 Hz, 3H), 1.05 
(s, 3H). 13C NMR (126 MHz, CDCl3) δ 166.4, 155.8, 143.3, 132.3, 129.7, 128.4, 128.3, 
125.5, 121.9, 120.0, 116.3, 72.6, 56.2, 51.6, 42.0, 40.0, 37.9, 35.3, 32.5, 30.5, 27.0, 
22.7, 18.6, 18.0, 13.6. IR (film) ʋmax 3170, 2949, 2917, 2849, 1692, 1496, 1484, 1453, 
1250, 1224, 756. DART-HRMS: m/z calculated for C27H33O3: 405.2430 [M-H]
+. Found: 
405.2437; calculated for C27H34O3NH4: 424.2852, [M+NH4]
+. Found: 424.2869. 
 (1R,3aR,4S,7aR)-1-((R)-sec-butyl)-7a-methyloctahydro-1H-inden-4-yl 3-hydroxy-
benzoate (98): 1H NMR (500 MHz, CDCl3) δ 7.65 (m, J = 7.7, 1.2 Hz, 1H), 7.61 (dd, J = 
2.6, 1.5 Hz, 1H), 7.38 – 7.31 (m, 1H), 7.08 (m, J = 8.1, 2.5, 1.0 Hz, 1H), 5.57 (s, 1H), 
5.43 (q, J = 2.8 Hz, 1H), 2.12 – 2.06 (m, 1H), 2.05 – 1.98 (m, 1H), 1.91 – 1.77 (m, 2H), 
1.64 – 1.43 (m, 6H), 1.41 – 1.30 (m, 2H), 1.25 (m, J = 7.9, 4.7, 2.6 Hz, 1H), 1.21 – 1.07 
(m, 2H), 1.06 (s, 3H), 0.95 (d, J = 6.4 Hz, 3H), 0.89 – 0.83 (m, 3H). 13C NMR (126 MHz, 
CDCl3) δ 166.7, 156.0, 132.5, 129.9, 122.1, 120.2, 116.6, 72.9, 56.1, 51.8, 42.1, 40.1, 
36.8, 30.7, 29.9, 28.3, 27.1, 22.2, 18.2, 18.2, 13.8. IR (film) ʋmax 3329 (br s), 3146, 3017, 
2950, 2931, 2867, 1671, 1613, 1584, 1485, 1466, 1250, 1208, 1137, 1088, 1061, 1032, 
937, 917, 755, 702, 666. DART-HRMS: m/z calculated for C21H30O3NH4: 348.2539 
[M+NH4]
+. Found: 348.2564. 
(1R,3aR,4S,7aR)-1-((R)-hexan-2-yl)-7a-methyloctahydro-1H-inden-4-yl 3-hydroxy-
benzoate (99): 1H NMR (500 MHz, CDCl3) δ 7.65 (d, J = 7.6 Hz, 1H), 7.58 (d, J = 2.6 
Hz, 1H), 7.39 – 7.31 (m, 1H), 7.12 – 7.04 (m, 1H), 5.43 (s, 1H), 5.41 – 5.31 (m, 1H), 2.14 
– 2.05 (m, 1H), 2.05 – 1.96 (m, 1H), 1.92 – 1.75 (m, 2H), 1.74 – 1.51 (m, 5H), 1.51 – 
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1.30 (m, 4H), 1.29 – 1.08 (m, 9H), 1.06 (s, 3H), 1.02 – 0.96 (m, 3H), 0.89 (t, J = 3.9 Hz, 
4H). 13C NMR (126 MHz, CDCl3) δ 166.4, 155.9, 132.5, 129.9, 122.2, 120.1, 116.5, 72.8, 
58.7, 51.8, 42.1, 40.0, 30.9, 30.7, 29.9, 27.5, 23.2, 22.9, 22.6, 22.2, 18.2, 14.2, 13.9. IR 
(film) ʋmax 3305 (br s), 3234, 2951, 2931, 2867, 2775, 1610, 1584, 1485, 1466, 1364, 
1346, 1250, 1208, 1137, 1086, 1062, 1032, 937, 917, 755, 715, 656. DART -HRMS: m/z 
calculated for C23H34O3NH4: 376.2887 [M+NH4]
+. Found: 376.2891 
(1R,3aR,4S,7aR)-1-((R)-heptan-2-yl)-7a-methyloctahydro-1H-inden-4-yl 3-hydroxy-
benzoate (100): 1H NMR (500 MHz, CDCl3) δ 7.65 (dd, J = 7.5, 1.6 Hz, 2H), 7.35 (t, J = 
8.0 Hz, 1H), 7.13 – 7.03 (m, 1H), 5.79 (s, 1H), 5.42 (dd, J = 4.1, 2.2 Hz, 1H), 2.08 (m, J 
= 11.3, 3.9 Hz, 1H), 2.05 – 1.97 (m, 1H), 1.93 – 1.71 (m, 2H), 1.56 (m, J = 18.9, 12.5, 
8.9, 4.5 Hz, 4H), 1.49 – 1.30 (m, 6H), 1.28 – 1.09 (m, 7H), 1.05 (s, 3H), 0.96 (dd, J = 
13.2, 6.2 Hz, 3H), 0.91 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 166.7, 156.0, 
132.4, 129.9, 122.1, 120.2, 116.6, 72.9, 56.6, 51.8, 42.1, 40.1, 35.8, 35.6, 32.5, 30.7, 
27.2, 25.9, 22.9, 22.9, 18.8, 18.2, 14.3, 13.8. IR (film) ʋ max 3375 (br s), 3138, 3011, 
2951, 2931, 2867, 1613, 1584, 1485, 1466, 1364, 1346, 1250, 1208, 1137, 1086, 1062, 
1032, 937, 917, 755, 704, 657. DART-HRMS: m/z calculated for C24H36O3NH4: 390.3008 
[M+NH4]
+. Found: 390.3045. 
(1R,3aR,4S,7aR)-7a-methyl-1-((R)-4-methylpentan-2-yl)octahydro-1H-inden-4-yl 3-
hydroxybenzoate (101): 1H NMR (500 MHz, CDCl3) δ 7.65 (d, J = 7.5 Hz, 1H), 7.59 (d, 
J = 6.8 Hz, 1H), 7.35 (q, J = 7.9, 7.3 Hz, 1H), 7.07 (d, J = 7.8 Hz, 1H), 5.42 (s, 2H), 2.17 
– 2.08 (m, 1H), 2.02 (d, J = 14.7 Hz, 1H), 1.94 – 1.77 (m, 2H), 1.55 (m, J = 52.3, 39.8, 
11.7, 6.8 Hz, 9H), 1.22 – 1.10 (m, 1H), 1.08 (s, 3H), 1.06 – 0.97 (m, 1H), 0.93 (d, J = 6.7 
Hz, 3H), 0.90 (d, J = 7.3 Hz, 4H), 0.87 – 0.82 (m, 3H). 13C NMR (126 MHz, CDCl3) δ 
166.5, 155.9, 132.5, 129.8, 122.1, 120.1, 116.5, 72.8, 57.6, 51.8, 45.7, 42.2, 40.2, 33.7, 
30.7, 29.9, 27.5, 24.9, 22.9, 21.5, 18.8, 18.2, 13.8. IR (film) ʋmax 3400 (br s), 3215, 2953, 
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2941, 2867, 2775, 1610, 1584, 1485, 1466, 1364, 1301, 1250, 1208, 1137, 1086, 1062, 
1032, 937, 917, 715. DART-HRMS: m/z calculated for C23H34O3NH4: 376.2853 
[M+NH4]
+. Found: 376.2868. 
(1R,3aR,4S,7aR)-7a-methyl-1-((R)-nonan-2-yl)octahydro-1H-inden-4-yl 3-hydroxy-
benzoate (102): 1H NMR (500 MHz, CDCl3) δ 7.65 (dd, J = 7.8, 1.3 Hz, 1H), 7.59 (dd, J 
= 2.6, 1.5 Hz, 1H), 7.34 (t, J = 7.9 Hz, 1H), 7.10 – 7.04 (m, 1H), 5.45 (s, 2H), 5.43 (s, 
1H), 2.12 – 2.05 (m, 2H), 2.05 – 1.98 (m, 1H), 1.93 – 1.76 (m, 3H), 1.65 (s, 2H), 1.62 – 
1.41 (m, 9H), 1.40 – 1.19 (m, 7H), 1.04 (d, J = 10.2 Hz, 3H), 0.99 (t, J = 6.9 Hz, 3H), 
0.89 (dd, J = 6.8, 2.0 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 166.7, 156.1, 132.5, 129.8, 
122.1, 120.2, 116.5, 72.9, 58.7, 51.8, 42.1, 40.0, 33.9, 30.9, 30.7, 30.3, 29.9, 29.8, 29.6, 
27.5, 22.9, 22.6, 18.8, 18.2, 13.9, 13.8. IR (film) ʋmax 3456 (br s), 2992, 2950, 2926, 
2907, 1712, 1699, 1485, 1466, 1364, 1346, 1250, 1208, 1137, 1086, 1062, 1032, 937, 
917, 715, 656. DART-HRMS: m/z calculated for C26H40O3NH4: 418.3982 [M+NH4]
+. 
Found: 418.3301. 
(1R,3aR,4S,7aR)-1-((R)-4,4-dimethylpentan-2-yl)-7a-methyloctahydro-1H-inden-4-yl 
3-hydroxybenzoate (103): 1H NMR (500 MHz, Chloroform-d) δ 7.79 – 7.54 (m, 2H), 
7.44 – 7.31 (m, 1H), 7.18 – 6.99 (m, 1H), 5.80 (d, J = 12.1 Hz, 1H), 5.42 (s, 1H), 2.17 – 
2.07 (m, 1H), 2.07 – 1.98 (m, 1H), 1.97 – 1.67 (m, 3H), 1.66 – 1.43 (m, 6H), 1.37 (dd, J = 
14.4, 7.0 Hz, 2H), 1.25 (d, J = 10.1 Hz, 1H), 1.20 – 1.11 (m, 1H), 1.09 (d, J = 1.7 Hz, 
1H), 1.06 – 0.99 (m, 1H), 0.99 – 0.85 (m, 11H).13C NMR (126 MHz, CDCl3) δ 166.5, 
155.8, 132.3, 129.7, 121.9, 120.0, 116.4, 72.8, 57.8, 51.7, 49.7, 42.0, 40.0, 32.4, 31.1, 
30.5, 30.4, 30.4, 29.7, 27.7, 22.7, 22.6, 18.0, 13.4. IR (film) ʋmax 3430 (br s), 3146, 3017, 
2950, 2931, 2867, 1671, 1613, 1584, 1485, 1466, 1374, 1346, 1250, 1208, 1137, 1088, 
1061, 1032, 937, 917, 755, 702, 666. DART-HRMS: m/z calculated for C24H36O3NH4: 
390.3008 [M+NH4]
+. Found: 390.3030. 
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 (1R,3aR,4S,7aR)-1-((R)-4-ethylhexan-2-yl)-7a-methyloctahydro-1H-inden-4-yl 3-
hydroxybenzoate (104): 1H NMR (500 MHz, CDCl3) δ 7.65 (m, J = 7.7, 1.1 Hz, 1H), 
7.58 (dd, J = 2.7, 1.5 Hz, 1H), 7.35 (m, J = 7.9, 2.1 Hz, 1H), 7.07 (m, J = 8.1, 2.7, 1.1 Hz, 
1H), 5.42 (q, J = 2.9 Hz, 1H), 5.29 (d, J = 4.4 Hz, 1H), 2.16 – 1.98 (m, 2H), 1.98 – 1.76 
(m, 2H), 1.64 – 1.29 (m, 8H), 1.28 – 1.04 (m, 8H), 1.01 – 0.79 (m, 10H). 13C NMR (126 
MHz, CDCl3) δ 166.5, 155.8, 132.6, 129.84122.2, 120.0, 116.5, 72.8, 57.8, 51.8, 42.2, 
39.8, 37.4, 33.6, 30.7, 29.9, 27.6, 26.8, 24.6, 22.9, 18.9, 18.2, 13.9, 11.5, 10.2. IR (film) 
ʋmax 3324 (br s), 3215, 2953, 2941, 2867, 2775, 1610, 1584, 1485, 1466, 1364, 1341, 
1250, 1208, 1137, 1086, 1062, 1032, 937, 917, 715, 656.  DART-HRMS: m/z calculated 
for C25H38O3NH4: 404.3208 [M+NH4]
+. Found: 404.3230. 
 (1R,3aR,4S,7aR)-1-((2R,5R)-5,6-dimethylheptan-2-yl)-7a-methyloctahydro-1H-
inden-4-yl 3-hydroxybenzoate (109): 1H NMR (500 MHz, CDCl3) δ 7.62 (m, 1H), 7.58 
(m, 1H), 7.32 (m, 1H), 7.05 (m, 1H), 5.58 (m, 1H), 5.39 (m, 1H), 2.05 (m, 1H), 1.98 (m, 
1H), 1.81 (m, 2H), 1.65 (m, 1H), 1.53 (m, 5H), 1.40 (m, 4H), 1.29 (m, 8H), 1.02 (s, 3H), 
0.93 (d, J = 6.6 Hz, 3H), 0.86 (d, J = 6.9 Hz, 3H), 0.78 (dd, J = 6.8, 3.4 Hz, 6H). 13C 
NMR (126 MHz, CDCl3) δ 166.4, 155.7, 132.2, 129.6, 121.9, 119.9, 116.3, 72.6, 56.2, 
51.5, 41.9, 39.8, 39.0, 35.8, 33.4, 31.4, 30.5, 30.4, 29.7, 27.0, 22.6, 20.5, 18.7, 18.0, 
17.5, 15.4, 13.5. IR (film) ʋmax 3400, 2956, 2939, 2868, 2858, 1700, 1684, 1601, 1589, 
1294, 1217, 1160, 1110, 946, 756, 680, 669. DART-HRMS: m/z calculated for 
C26H40O3NH4: 418.3321 [M+NH4]
+. Found: 418.3306. 
(1R,3aR,4S,7aR)-1-((2R,5S,E)-5,6-dimethylhept-3-en-2-yl)-7a-methyloctahydro-1H-
inden-4-yl 3-hydroxybenzoate (111): 1H NMR (500 MHz, CDCl3) δ 7.61 (m, 2H), 7.31 
(m, 1H), 7.06 (m, 1H), 5.98 (br s, 1H), 5.39 (m, 1H), 5.18 (m, 2H), 2.01 (m, 3H), 1.81 (m, 
2H), 1.68 (m, 1H), 1.49 (m, 6H), 1.24 (m, 4H), 1.15 (m, 1H), 1.04 (m, 3H), 1.02 (d, J = 
6.5 Hz, 3H), 0.91 (d, J = 6.8 Hz, 3H), 0.73 (m, 6H). 13C NMR (126 MHz, CDCl3) δ 162.0, 
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136.8, 127.9, 127.4, 125.1, 122.4, 120.7, 111.8, 108.2, 72.5, 69.4, 56.7, 56.5, 52.6, 51.6, 
42.0, 41.8, 40.4, 39.9, 39.5, 39.4, 35.9, 35.9, 35.4, 35.2, 33.6, 30.6, 28.0, 27.1, 27.0, 
23.8, 23.7, 22.8, 22.6, 22.5, 18.6, 18.5, 18.0, 17.4, 13.5, 13.4. IR (film) ʋmax 3184, 3146, 
3017, 2950, 2931, 2867, 1671, 1613, 1584, 1485, 1466, 1374, 1346, 1325, 1301, 1250, 
1208, 1137, 1088, 1061, 1032, 937, 917, 883, 800, 755, 702, 666. DART -HRMS: m/z 
calculated for C26H38O3NH4: 416.3165 [M+NH4]
+. Found: 416.3171. 
(1R,3aR,4S,7aR)-1-((S)-1-hydroxypropan-2-yl)-7a-methyloctahydro-1H-inden-4-yl 3-
hydroxybenzoate (113): 1H NMR (500 MHz, CDCl3) δ 7.63 (d, J = 7.6 Hz, 1H), 7.56 (d, 
J = 2.1 Hz, 1H), 7.34 (t, J = 7.8 Hz, 1H), 7.09 (dd, J = 8.2, 2.8 Hz, 1H), 5.66 (s, 1H), 5.39 
(d, J = 3.3 Hz, 1H), 4.76 (s, 1H), 4.32 (dd, J = 10.8, 3.6 Hz, 1H), 4.12 (m, J = 17.6, 11.1, 
5.6 Hz, 1H), 2.10 (m, J = 13.3, 3.4 Hz, 1H), 2.04 – 1.85 (m, 2H), 1.83 – 1.74 (m, 3H), 
1.61 (m, J = 8.9, 5.0 Hz, 4H), 1.44 (m, J = 14.2, 6.1, 4.8 Hz, 2H), 1.14 (d, J = 6.6 Hz, 
3H), 0.97 (d, J = 7.8 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 166.7, 156.1, 132.1, 129.8, 
122.0, 120.3, 116.4, 74.768, 70.0, 53.1, 51.0, 42.2, 39.6, 35.8, 30.4, 26.2, 22.6, 17.6, 
17.4, 13.0. IR (film) ʋmax 3621, 3464, 3385 (br s), 3019, 2951, 2868, 1599, 1589, 1466, 
1453, 1366, 1295, 1215, 1157, 1106, 1075, 1062, 982, 946, 886, 755, 680, 668. DART -
HRMS: m/z calculated for C20H27O3: 315.1960 [M-OH]
+, Found: 315.1983. 
3. Biological evaluation 
3.1 Experimental protocols  
Cell line maintenance and general protocols: C3H10T1/2 cells were purchased 
from American Type Culture Collection (ATCC). ASZ001 cells were a generous gift of 
Dr. Ervin Epstein (Children’s Hospital of Oakland Research Institute) . Gibco by Life 
Technologies culture media was purchased from ABI. C3H10T1/2 cells were cultured in 
BME (Gibco) supplemented with 10% FBS (Atlanta Biologicals, Premium Select), 1% L-
glutamine (Cellgro; 200 nM solution), and 0.5% penicillin/streptomycin (Ce llgro; 10,000 
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I.U./mL penicillin, 10,000 μg/mL). ASZ001 cells were cultured in 154CF media, 
supplemented with 2% FBS (chelexed, heat-inactivated), 1.0% penicillin/streptomycin, 
and a final concentration of 0.05mM CaCl2. Cells were maintained using the media 
described above (denoted “growth media”). Media denoted as “low FBS” contained 0.5% 
FBS and the same percentage of other supplements as specified for growth media (“low 
FBS” media with this percentage FBS was used for C3H10T1/2 cell assays). Following 
plating and 24 hr growth period, no FBS supplemented media was used for ASZ001 cell 
assays. All cells were grown in Corning Cell Culture, canted neck T75 or T150 flasks 
(Fisher Scientific) in an Autoflow IR water-jacketed CO2 incubator (37°C, 5% CO2). 
Experiments with C3H10T1/2 cells were performed in BD Falcon sterile 60 mm dishes. 
500,000 cells at ~80% confluence were plated in 5 mL media. Experiments with ASZ001 
cells were performed in BD Falcon 35 mm dishes or in 6-well, 35mm plates. For the 
ASZ001 line, 300,000 cells at ~80% confluence were plated in 2 mL media. DMSO was 
used as solvent to prepare all drug solutions and the final DMSO concentration did not 
exceed 0.3%. 20α-hydroxycholesterol, 22(S)-hydroxycholesterol (Oxysterol/Oxy) and 
VD3, for biological studies, were purchased from Sigma-Aldrich.  
Analysis of Hh and VDR target gene expression in C3H10T1/2 cells:  Cells were 
plated in growth media at ~80% confluence. Once cells reached confluence 
(approximately 24 hr), growth media was removed and replaced with low FBS media (5 
mL). This was followed by addition of Oxy, Oxy and analogue, or DMSO (vehicle 
control). Cells were incubated (37°C, 5% CO2) for 24 hr period and RNA was isolated 
and evaluated by qRT-PCR analysis as described previously in Chapter 2. Data was 
analyzed using GraphPad Prism 5 and IC50 values computed as mean ± SEM from at 
least three separate experiments performed in triplicate.  
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Analysis of Hh and VDR target gene expression in murine-derived BCC 
(ASZ001) cells: Cells were plated in growth media at ~80% confluence. After 24 hr, 
growth media was removed and replaced with no FBS media (2 mL). Cells were then 
incubated for an additional 24 hrs. After this time, addition of DMSO (vehicle control) or 
analogues was performed. Cells were incubated (37°C, 5% CO2) for 48 hr and RNA was 
isolated and evaluated by qRT-PCR analysis as described previously. Data was 
analyzed using GraphPad Prism 5 and IC50 values computed as mean ± SEM from at 
least three separate experiments performed in triplicate. 
3.2 Results & discussion 
 
Figure 4. VD3 based hybrid side chain analogues. 
This series of hybrid side chain analogues prepared for evaluation can be 
broadly categorized into two groups, i.e. hydrocarbon containing and non-hydrocarbon 
containing side chain analogues (Figure 4). Further, the first group has representatives 
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for linear alkyl side arms (93, 94, 98, 99, 100 and 102), branched alkyl chains (95, 101, 
103, 104, 109) branched alkenyl side chains (111) as well as an aromatic side chain 
derivative (96). On the other hand, analogue (113) is the only non-hydrocarbon 
containing side chain analogue.  
The initial evaluation of all hybrid VD3 side chain analogues as Hh pathway 
inhibitors was performed at a single dose (5 μM) by monitoring endogenous Gli1 mRNA 
levels in C3H10T1/2 cells following standard assay protocols 108, 111. At this 
concentration, excluding 99, 101, 102, and 103, other derivatives maintained similar 
potency (0.5-10% Gli1 mRNA expression).  Moreover, inhibitory activities of the latter 
were comparable to the previously identified VD3-based lead scaffold 87 and improved 
compared to that of VD3 (Table 1). Thereafter, relative mRNA expression levels of Gli1 
were examined after treatment of C3H10T1/2 cells with a lower concentration (2.5 μM) 
(Table 1). At this dose, differences between assay readouts from treatments with 
different analogues were more pronounced and thus it was possible to identify 
analogues that maintained potent anti-Hh activity even at a lower concentration. Based 
on the data from treatments at two different doses, the optimum length of linear side 
chain proved to be critical in maintaining potent Gli1 inhibitory activity. Derivatives with 
shorter 93, 94, 98 and 99 or longer 102 chain lengths than the naturally occurring six-
carbon side arm present in VD3 suffered losses in potency. In agreement with this 
general trend, 100 retained Hh antagonistic activity similar to the lead structure 87 in this 
cellular model. Several interesting effects on the inhibitory activity profile were observed 
on introduction of branched side chains. Analogues with very short branched chains 101 
and 103 were less active than the parent scaffold. However, iso and ante-iso branching 
incorporated into five-carbon long side chain (95 and 104 respectively) salvaged the loss 
in potency seen in the unbranched derivative with a comparable length side arm (99). In 
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terms of favorable features unraveled so far, 109 had a combination of extended six-
carbon link primary chain along with terminal and non-terminal branching in the same 
molecule. Nonetheless, instead of the expected synergistic outcome of all these features 
incorporated in one derivative, deleterious effects on the level of Gli1 inhibition were 
observed. Interestingly, an additional unsaturation present in the side chain of this 
molecule helped to restore the diminished activity. Consequently, analogue 111 with 
comparatively rigid side arm exhibited slightly greater than two-fold improvement in 
activity as compared to relatively flexible analogue 109. Finally, no improvement in 
activity was evident for the aromatic side chain containing derivative 96 or hydroxyl side 
chain analogue 113. It is unclear whether the loss of activity in these cases can be 
attributed singularly to the planar/polar nature of these substituents respectively. 
Analysis of specific contributions of the length of the connecting carbon chains extending 
these functionalities spatially remains the subject of further investigation.  
Table 2. Gli1 inhibitory activity in C3H10T1/2 cells. 
Analogue Relative Gli1 mRNA (%)
a
 
 5 µM treatment 2.5 µM treatment 
VD3 31.7 ± 0.7 71.4 ± 2.1 
87 1.9 ± 0.5 15 ± 2.0 
93 1.31 ± 0.1 49.8 ± 1.8 
94 7.7 ± 5.5 69.8 ± 27.2 
95 2.9 ± 0.3 23.0 ± 4.3 
96 7.2 ± 1.8 88.4 ± 55.4 
98 0.7 ± 0.3 33.9 ± 13.1 
99 38.4 ±4.15 52.3 ± 13.2 
100 1.1 ± 0.3 17.3 ± 3.6 
101 74.4 ± 0.7 90.1 ± 12.5 
102 29.9 ± 16.1 54.4 ± 9.7 
103 32.4 ± 28.93 49.1 ± 19.6 
                104 0.49 ± 0.2 17.4 ± 4.5 
109 9.2 ± 6.1 40.4 ± 9.5 
111 2.2 ± 0.5 15.6 ± 0.9 
113 10.2 ± 6.1 56.9 ± 10.2 
a
Relative Gli1 mRNA levels w hen oxysterol treatment is equivalent to 100%. 
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After establishing the effects on Hh inhibitory activity by varying the nature of CD-
ring appendages and thereby identifying favorable modifications, we directed our efforts 
towards assessing their effects on the selectivity profile of representative analogues. 
Previously, VD3 was shown to be a non-selective inhibitor of the Hh pathway, 
presumably due to its propensity to undergo metabolic transformation to form calcitriol 
and activate canonical VDR signaling 108. It is noteworthy that as per the known route to 
such biotransformations, hydroxylations of the A-ring and the CD-ring side chain are 
required to yield ligands for VDR activation (Chapter 2, Figure 3). Since the 
modifications of A-ring led to improved selectivity for potent analogue 87, we were 
interested in studying the repercussions of further altering the side chain region of this 
lead compound. 
Table 3. VDR related activity mediated by hybrid side chain analogues. 
Analogue Relative Cyp24A1 mRNA
b
 VDR Binding  Conc. 
VD3 4004 ± 56 >100 µM 
87 10.5 ± 2.1 >100 µM 
93 0.7 ± 0.2 >100 µM 
94 4.8 ± 0.9 >100 µM 
95 2.8 ± 0.03 >100 µM 
96 3.8 ± 0.1 >100 µM 
98 1.1 ± 0.3 >100 µM 
99 4.9 ± 0.5 >100 µM 
100 4.4 ± 0.03 >100 µM 
101 2.5 ± 1.0 >100 µM 
102 3.8 ± 0.7 >100 µM 
103 7.9 ± 1.4 >100 µM 
                104 0.6 ± 0.02 >100 µM 
109 1.1 ± 0.02 >100 µM 
111 6.8 ± 0.02 >100 µM 
113 0.4 ± 0.1 >100 µM 
b
Values represent Cyp24A1 mRNA expression level in cultured cells w hen DMSO set as 1.0. 
None of these derivatives directly bind to VDR as measured in the previously 
described in vitro VDR binding assay even at a high concentration of 100 µM (Table 3). 
Since C3H10T1/2 cells respond to VDR activation with robust up-regulation of Cyp24A1, 
a well-characterized target gene of canonical vitamin D signaling; we then studied off -
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target effects mediated due to potential metabolism of VD3 analogues in this system 
(Table 3). Overall, every hybrid side chain analogue maintained the selectivity for Hh 
inhibition without concomitant activation of VDR signaling. Moreover, analogues such as 
95, 100, 104 and 111 afforded slightly improved selectivity over 87 while maintaining 
better potency for Hh inhibition. Based on the fact that changing the side chain regio n 
didn’t have drastic consequences on the selectivity profile, it can be hypothesized that 
optimum changes to the A-ring region can suffice to mitigate side effects of the original 
VD3 scaffold. However, additional fine tuning of selectivity can be achieved by above 
noted alterations to the side chain region. 
Previous studies evaluating Hh pathway inhibition in cultured cancer cells have 
suggested that the majority of in vitro cancer cell lines do not appropriately model in vivo 
Hh signaling. With this in mind, we sought to characterize VD3 and related analogues in 
a cell line, ASZ001, which has shown initial promise as in vitro model of oncogenic Hh 
signaling. The ASZ001 cell line was developed from a visible BCC tumor isolated from a 
Ptch1+/- mouse 163. These cells demonstrate loss of the wildtype Ptch1 allele, high 
baseline expression of Gli1, and cellular morphology similar to Hh-dependent BCC 
tumors. In addition, treatment of these cells with either Cyc or VD3 resulting in Gli1 
down-regulation has been previously reported 110, 163. Previous studies performed in this 
cell line demonstrated that Gli1 down-regulation by VD3 in ASZ001 was more robust and 
reproducible following a 48 h compound incubation 110. Preliminary evaluation in our lab 
was consistent with a 48 h incubation period resulting in reproducible Gli1 down -
regulation induced by GDC-0449 or Cyc. For this reason, all data presented from this 
cell line were obtained at this time point. 
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Figure 5. Hh specific activity of hybrid side chain analogues in ASZ001 cells.  
Initially, we evaluated the Hh specific activity of the hybrid side chain analogues 
in the ASZ001 cells at a single dose of 2.5 μM by quantifying relative mRNA expression 
levels of Hh responsive gene, Gli1, and VDR dependent gene, Cyp24A1, simultaneously 
(Figure 5). It had been previously established in our lab that the IC50 for VD3 down-
regulation of Gli1 in ASZ001 cells correlated well with that obtained in the C3H10T1/2 
fibroblasts, however; analogue 87 proves to be less effective in this model 113, 114. 
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Consistent with that observation, the extent of Gli1 downregulation in this cellular system 
by hybrid side chain derivatives was less than the levels observed in its MEF 
(C3H10T1/2) counterpart. The analogues demonstrating most prominent Hh inhibitory 
activity included 94, 95, 96, 99, 102 and 113. While the selective and potent Hh 
antagonistic activity of 95 was consistent with its activity profile previously identified in 
C3H10T1/2 cells. It was intriguing to note that several of the more active analogues in 
ASZ001 cells such as linear side arm-containing analogues (94, 99 and 102), 
hydroxylated side arm-containing analogue (113) and aromatic functional group 
containing (96) had demonstrated modest Hh inhibitory activities in C3H10T1/2 cells. 
Taking into account the comparatively higher Cyp24A1 expression mediated by 99 and 
102, the improved Hh inhibiton as a result of crosstalk between signaling cascades can 
be speculated. Next, although 96 and 113 did not demonstrate increased levels of 
Cyp24A1, these analogues caused excessive cell death at higher doses (5 μM and 
above) suggestive of additional non-specific mechanisms of toxicity. Nonetheless, the 
plausible reason for improved anti-Hh activity of 94 is unclear. Next, derivatives that 
maintained slightly less Gli1 inhibition than the above discussed analogues included 93, 
100, 103 and 104. While their Hh inhibitory activities were comparable to that of VD3, 
off-target effects via VDR signaling were minimal as depicted by low Cyp24A1 
expression. Finally, analogues that failed to reduce Gli1 expression in ASZ001 included 
98, 101, 109 and 111. Once again, the drastic loss in activity of 111 in ASZ001 cells is in 
total contrast with its excellent potency observed in C3H10T1/2 cells. Taken together, 
there was a lack of definitive SAR trend in this cell based assay and further studies are 
required to corroborate the theories proposed to explain the discrepancies.  
Based on the preliminary screening of active and specific Hh inhibitors, we 
decided to conduct further studies on analogues that exhibited an optimum 
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activity/selectivity ratio across both cellular systems. Therefore, we conducted 
concentration dependent analysis of Gli1 inhibitory potential of analogues 95, 100 and 
104 in both Hh signaling inducible MEF cells (C3H10T1/2) and murine BCC cells 
(ASZ001) (Figure 12). When tested in C3H10T1/2 cells, all three derivatives 
demonstrated low micromolar IC50 values for Gli1 downregulation. In ASZ001 cells, 95 
maintained comparable low micromolar potency. Although, 100 and 104 retain Hh 
inhibitory activity, slightly higher IC50 values were recorded.  
Table 4. Determination of IC50 values in C3H101/2 cells and ASZ001 cells. 
Analogue Structure IC50 (μM) 
  C3H10T1/2 ASZ001 
95 
 
1.13 ± 0.56 1.61 ± 0.15 
100 
 
1.10 ± 0.37 6.57 ± 2.78 
104 
 
1.14 ± 0.45 
4.98 ± 2.87 
 
4. Conclusion 
With the goal of identifying improved Hh antagonists, we studied the effects of 
modifying the side chain region of VD3. During the initial phase of this study, a VD3 
based Hh selective lead compound (87, IC50 = 0.74 ± 0.1 μM) was identified in a parallel 
project. Subsequently, our investigation on side chain analogues of VD3 proceeded with 
altered CD-ring appendages installed on the novel VD3 based lead compound. A series 
of fourteen diverse side chain derivatives were prepared and evaluated in two different 
cellular models of Hh inhibition. Overall, linear or moderately branched hydrocarbon 
chains of five/six carbon links proved to be optimum for potent and selective anti -Hh 
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activity. Analogue 95 showed consistent improved performance in various cellular and 
other in vitro assays designed to determine Hh inhibition and VDR activation.  
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CHAPTER IV: Design, Synthesis and Evaluation of Itraconazole Analogues 
Incorporating Modified Side Chains as Hedgehog Pathway Inhibitors 
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1. Introduction 
One of the latest challenges to emerge in the discovery and development of safe and 
efficacious Hh inhibitors as anti-cancer agents is the retention of comparable activity 
against the drug-resistant forms of the hyperactive signaling cascade 89. Recently 
identified as a potent inhibitor of the Hh pathway (IC50 approximately 800 nM) 
116, 
itraconazole (ITZ) represents an extremely promising scaffold for the development of an 
improved class of Hh inhibitors for two important reasons. First, being a well-studied and 
widely used FDA approved antimycotic drug, the PK properties and safety profile of ITZ 
is very well documented 164. Thus, the strategy of repurposing this previously approved 
drug will simplify and expedite the otherwise long-drawn process of drug discovery and 
clinical approval. Second, a recent study detailing the ability of ITZ to maintain potent 
inhibition of Hh signaling even in the presence of multiple mutant forms of Smo that 
confer resistance to either GDC-0449 or NVP-LDE225 was reported 101. This finding is 
especially significant in the context of developing anti-Hh agents active against drug 
resistant cases of BCC and MB.  
ITZ is a member of the triazole class of antifungal agents that exerts its 
antimycotic effects through potent inhibition of lanosterol 14α-demethylase (14LDM/ 
CYP51), a cytochrome P450 enzyme that catalyzes the oxidative conversion of 
lanosterol to ergosterol, a major component of fungal cell membranes 165. The main 
structural regions of ITZ are a triazole-dioxolane portion, a central phenyl-piperizine-
phenyl linker region and a side chain appended triazolone region (Figure 1). Further, the 
molecule possesses three chiral centers, two of which are on the dioxolane ring (2 and 
4) while the third exists on the sec-butyl side chain (2’). Out of the eight possible 
stereoisomers, a mixture of four cis-isomers (1:1:1:1) is marketed as the antifungal drug. 
Previous investigations have confirmed that ITZ mediated Hh inhibition is unrelated to 
the 14-α-lanosterol demethylase inhibition accountable for its anti-fungal activity 116. 
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Following the identification of ITZ as Hh inhibitor, only a single report detailing SAR for 
ITZ inhibition of Hh signaling has been reported to date. These studies focused solely on 
incorporating modified alkyl substituents into the ITZ side chain 120.  
 
Figure 1. Structure, stereo-centers and regions of ITZ. 
Despite the expected favorable outcomes of exploring the ITZ molecule for 
developing novel Hh inhbitors, several key tasks remain. Identifying the Hh inhibitory 
pharmacophore of ITZ is critical for guiding further modifications to suit the current 
purpose and enhance the potency and efficacy of the parent moiety by suitable 
modifications of the active core. Moreover, this knowledge will allow us to further 
improve the physicochemical features and bioavailability of second generation ITZ 
analogues which can be critical especially for clinical use in MB patients where blood -
brain-barrier (BBB) penetration and accumulation is of utmost significance.  Previous 
studies undertaken in Shh-Light II cells have indicated that other azole drugs 
(Ketoconazole, Fluconazole, Miconazole and Clotrimazole) that share structural features 
with ITZ and have comparable or better anti-fungal activities, exhibit decreased 
potencies as inhibitors of Smo 116. To corroborate these findings, we evaluated several 
commercially available, structurally related triazole and imidazole anti-fungals for their 
ability to inhibit Hh signaling at 1 μM in the C3H10T1/2 murine fibroblast cell line when 
recombinant Sonic Hh protein was used to up-regulate Hh signaling (Figure 2, Table 1). 
We discovered that only Posaconazole (PSZ) maintained Hh inhibition comparable to 
ITZ in this assay. Interestingly, ITZ and PSZ share considerable structural and spatial 
similarity with certain differences in the triazole-dioxolane and triazolone side chain 
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regions of the molecules. Therefore, we were interested in studying the effects of 
integrating the structural features of PSZ with ITZ as hybrid second generation 
analogues. Keeping in mind the issues of poor water solubility and low bioavailability of 
ITZ 166, initial efforts were directed towards the generation of hydroxylated side chain 
containing ITZ derivatives to simultaneously achieve the goals of improving potency as 
well as physicochemical and pharmacokinetic attributes. A report of our current progress 
in identifying a suitable synthetic route to prepare ITZ derivatives with stereochemically 
defined hydroxylated side chains as mimics of the PSZ side arm and a brief description 
of preliminary biological evaluation is presented in this chapter.  
 
Figure 2. Structure of commercial azole antifungal drugs tested for Hh inhibition. 
Table 1. Hh Inhibition for Commercially Available Azole Antifungals.  
Compound Relative Gli1 mRNA (%) 
Recombinant SHh 100 
ITZ 4.8 ± 2.1 
PSZ 5.1 ± 3.6 
Fluconazole 75.3 ± 1.6 
Miconazole 63.2 ± 8.1 
Compound Relative Gli1 Mrna (%) 
Voriconazole 48.4 ± 7.4 
Ravuconazole 35.2 ± 1.4 
Albaconazole 44.5 ± 6.2 
Terconazole 59.0 ± 10.6 
Ketoconazole 43.9 ± 0.3 
a
Relative Gli1 mRNA levels w hen SHh treatment is equivalent to 100%. 
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2. Synthesis of ITZ-PSZ hybrid analogues  
2.1 Overview 
Preparation of ITZ-PSZ hybrid analogues was accomplished through an optimized 
multistep route specifically planned for facile medicinal chemistry purposes of accessing 
stereochemically defined hydroxylated side chain derivatives of ITZ. The essential 
synthetic transformations can be classified as follows: (a) synthesis of hydroxylated side 
chain precursors (A), (b) synthesis of MOM-ITZ triazolone linker region intermediate (B), 
(c) alkylation of MOM-ITZ triazolone linker region intermediate (C) followed by 
deprotection to generate necessary phenolic intermediates (D), (d) synthesis of tosylated 
dioxolane intermediate (E) and (e) nucleophilic displacement of the tosyl moiety by 
phenolic precursors to generate final analogues (Scheme 1).  
 
Scheme 1. Retrosynthesis of ITZ-PSZ hybrid analogues 
Preparation of hydroxylated side chain precursors (A) was carried out using 
stereochemically defined starting materials methyl (R)-2-hydroxylpropanoate (122) or 
methyl (S)-2-hydroxylpropanoate (123). Masking the free hydroxyl groups as silyl ethers, 
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the resulting intermediates (124) and (125) were subjected to reduction by DIBAL-H to 
yield the corresponding aldehyde derivatives (126) and (127). Even with strictly 
controlled temperature of -78 ºC, some of the starting esters underwent complete 
reduction to form the corresponding alcohol derivatives (128 and 129) and selective 
generation of required aldehyde precursors proceeded with modest yields. Hence, 
attempts to reoxidize the hydroxylated derivative back to the aldehyde stage were made 
by utilizing PDC and Dess Martin Periodinane reagents respectively. While reaction with 
PDC led to the generation of partial oxidation product i.e. necessary aldehyde along with 
unwanted complete oxidation product (corresponding carboxylic acid), the reaction 
proceeded more successfully with the Dess Martin Periodinane conditions. Despite the 
success, these routes of recycling the alcohol derivatives back to the aldehyde 
precursors proved less favorable as there was unnecessarily addition to the overall 
steps required to generate final compounds. Therefore, we employed the previous 
strategy of ‘selective’ reduction with DIBAL-H on a larger scale reaction to prepare 
necessary amounts of intermediates (126 and 127) taking into consideration the 
expected reaction yields. These intermediates were then subjected to nucleophilic 
addition by ethylmagnesium bromide to prepare and isolate precursors (130-133). As 
expected, the presence of bulky silyl ether protecting group on the adjacent hydroxyl 
directed the addition following the Felkin Ahn model, generating the predominantly ‘anti’ 
derivatives with an overall yield of 60-72% in a 3:1 (anti:syn) ratio. Finally, the free 
hydroxyl moieties were converted to corresponding brosyl functionalities to yield 
intermediates (A: 134-139) (Scheme 2).  
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Scheme 2. Synthesis of hydroxylated side chain precursors (A). 
A previously reported literature protocol was followed for the synthesis of MOM-
ITZ triazolone linker region (B: 144) 120. We proceeded by coupling commercially 
available N-(4-hydroxylphenyl)-piperazine (140) and 1-chloro-4-nitrobenzene (141) to 
yield N-(4-hydroxyphenyl)-N′-(4-nitrophenyl)-piperazine derivative. This crude product 
was directly used to react with methoxymethyl chloride to afford the MOM-protected 
intermediate (142). Subsequent reduction of the nitro group of (142) afforded the 
corresponding amine derivative precursor necessary for the synthesis of 
phenylcarbamate derivative (143). Ultimately, synthesis of the triazolone heterocycle 
was accomplished via formation of the semicarbazide intermediate from precursor (143) 
(Scheme 3). 
 
Scheme 3. Synthesis of MOM-ITZ triazolone linker region intermediate (B). 
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Next, alkylation of triazolone intermediate (B) was attempted by using Cs2CO3 in 
the presence of 18-crown-6 at room temperature to generate the anion of (B) to facilitate 
SN2 displacement of the brosylate intermediates (A) 
120. However, with secondary 
brosylates such as (135), the reaction failed to proceed under these conditions in either 
DMF or DMSO (Table 2). Thereafter, the reaction was subjected to an elevated 
temperature of 80 ºC affording better results 167. Under these revised conditions, the 
reactions proceeded to completion to form intermediates (145) and (146), however; 
unreacted starting materials were recovered when using the sterically hindered 
brosylates (134-137). Subsequently, the reaction mix was heated at 50 ºC with the base 
(Cs2CO3) and the chelator (18-crown-6) to enhance the nucleophile formation before 
addition of sterically crowded brosylate intermediates. Further, the reaction was heated 
overnight at 80 ºC to facilitate the complete consumption of starting materials leading to 
improved yields of (C: 147-150).  The final step to generate phenolic precursors (D: 151-
156) was accomplished by global deprotection of methoxymethyl and silyl ether groups 
using trifluoroacetic acid (Scheme 4). 
 
Scheme 4. Synthesis of phenolic precursors (D). 
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Table 2. Optimization of reaction conditions for alkylation of (B). 
Reaction conditions Observations 
Reaction 
yields 
CsCO3, 18-crow n-6, DMSO, rt, 1h; (135), rt 12h No reaction - 
CsCO3, 18-crow n-6, DMF, rt, 1h; (135), rt 12h No reaction - 
CsCO3, 18-crow n-6, DMF, rt, 1h; (135), 80ºC, 12h Some unreacted starting material 30% 
CsCO3, 18-crow n-6, DMF, 50 ºC , 1h; (135), 80ºC, 12h Reaction complete 57% 
CsCO3, 18-crow n-6, DMF, rt, 1h; (138 /139), 80ºC, 12h Reaction complete 62% 
Formerly reported literature methods for preparing the tosylated-dioxolane 
intermediate (E) were adopted with slight modifications to generate the intermediate as a 
mixture of both cis and trans isomers 168, 169. Beginning with a protected glycerol 
intermediate (157), the free primary hydroxyl group was first transformed to the 
corresponding tosylate (158), followed by a deprotection step to yield mono-tosylated 
glycerol (159). In parallel, trichloroacetophenone (160) was utilized to facilitate 
substitution of chloro group with triazole functionality leading to precursor (161). 
Ultimately, triflic acid mediated ketalization using (159) proceeded to generate 
intermediate (E: 162) as a mixture of cis (major product) and trans (minor product) 
isomers (Scheme 5).  
 
Scheme 5. Synthesis of tosylated dioxolane intermediate (E).  
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The final step consisted of coupling the tosyl-dioxolane intermediate (E) with 
each of the phenolic precursors (D). Initial attempts of base assisted generation of the 
phenoxy nucleophile were performed using NaH in DMSO at elevated temperatures (50 -
90 ºC) 120, 170. Adopting this protocol, final analogues (163 and 164) were synthesized in 
modest yields (Scheme 6). However, the purification steps of these analogues proved 
extremely challenging owing to the difficulties of removal of DMSO and several side 
products possibly formed due to the action of NaH in DMSO in the presence of free 
hydroxyl groups at elevated temperatures. Consequently, these analogues were isolated 
at 80-85% purity levels as determined by NMR spectral data. Thereafter, multiple efforts 
to couple tosyl-dioxolane intermediate (E) with phenolic precursors containing bulkier 
hydroxylated side appendages (153-156) failed. While, desired analogues were not 
detected in these reaction mixtures, the starting precursors had been consumed to form 
complex compounds of unknown structures. Based on the observat ions of typical color 
changes associated with ylide formation, it was hypothesized that under the 
aforementioned conditions, DMSO was participating in the reaction possibly through its 
activation to form sulfur ylides. As an alternate, DMF was employed as a solvent to 
successfully synthesize 165 with 20% yields (Scheme 6). This final coupling step is 
currently underway for other phenolic precursors.  
 
Scheme 6. Synthesis of ITZ-PSZ hybrid analogues. 
 92 
 
2.2 Experimental protocols 
General procedure for TBS protection: To a solution of methyl (R)-2-
hydroxylpropanoate or methyl (S)-2-hydroxylpropanoate (5 g, 1 eq.) in anhydrous DCM 
(60 mL) was added imidazole (4.25 g, 1.3 eq.), and the mixture was stirred for 10 min at 
0 °C. To this solution tert-butyldimethylsilyl chloride (8.68 g, 1.2 eq.) was added at 0 °C 
and the mixture was allowed to warm to RT and stirred overnight. After completion of the 
reaction, the mixture was diluted with water and extracted into DCM. The combined 
extract was washed with brine, dried over anhydrous Na2SO4 and concentrated under 
reduced pressure. The crude residue was purified by column chromatography (SiO2, 0-
5% EtOAc in hexanes) to give pure compounds (124) and (125) as colorless oils in 95 % 
yields.  
General procedure for reduction to aldehyde: To a cooled (-78 °C), stirred 
solution of ester compounds (124) or (125) (5 g, 1 eq.) in anhydrous DCM (50 mL) was 
slowly added DIBAL-H (1.0 M, 2 eq.) and stirred for 2 h. The reaction was quenched with 
saturated sodium potassium tartarate (50 mL), stirred for 0.5 h and then filtered using 
excess DCM. The combined organic phases were separated, washed with brine, dried 
over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product 
was purified by column chromatography (SiO2, 0-5% EtOAc in hexanes) to give 
aldehydes (126) and (127) as a colorless liquids in 30-40 % yields. 
General procedure for nucleophilic addition of Grignard reagents: Aldehyde 
(126) or (127) (1 g, 1 eq.) in anhydrous THF (20 mL) was added dropwise to 
ethylmagnesium bromide (3.0 M in anhydrous THF, 5 eq.) at -78 °C and the reaction 
mixture was stirred for 2 h. After completion, the reaction mixture was quenched with 
water and extracted into EtOAc. The combined organic layer was washed with 0.1N HCl, 
brine, dried over Na2SO4, and concentrated. The crude residue was purified by column 
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chromatography (SiO2, 0-15% EtOAc in hexanes) to carefully separate the resulting 
isomers (130-133) as a colorless oils in good yields [130 & 131: 72% (1:3); 132 & 133: 
60% (3:1)]. 
General procedure for brosylation: To a solution of hydroxyl intermediate 
128/129/130/131/132/133 (0.1- 0.12 g, 1 eq.) in anhydrous DCM (3-5 ml), triethylamine 
(2 eq.), dimethylaminopyridine (1 eq.)  and 4-bromobenzene-1-sulfonyl chloride i.e. BsCl 
(1.3 eq.)  were added at 0 °C. The reaction mixture was allowed to warm to RT while 
stirring overnight. On completion, the mixture was diluted with DCM, washed with water, 
dried over Na2SO4 and concentrated under reduced pressure. Purification using column 
chromatography (SiO2, 0-10% EtOAc in hexanes) yielded intermediates (A: 134-139) as 
clear oils in 65-80% yields. 
General procedure for alkylation of linker region: To a solution of the linker 
region triazolone intermediate, (C), (1 eq.) in DMF was added Cs2CO3 (2 eq.) and 18-
crown-6 (1 eq.). The resulting mixture was stirred at 50 ºC for 1 h followed by the 
addition of corresponding alkyl brosylates A: 134-139 (1.5 eq.). The reaction mixture 
was stirred overnight at 80 ºC. After cooling to room temperature, the reaction mixture 
was diluted with water and extracted with EtOAc. The combined organic layer was dried 
over Na2SO4, filtered, and concentrated to yield the crude product. Purification by 
column chromatography (SiO2, 0-3% MeOH in DCM) afforded pure products (C: 145-
150) as a brown solid in 30-62% yields.  
General procedure for coupling phenol intermediates (D) and tosylated 
dioxolane intermediate (E): To a solution of the phenol D (1 eq.) in DMF was added 
NaH (a 60% dispersion in mineral oil, 5 eq.). After the mixture was stirred at 50 °C under 
argon for 1 h, a solution of E (1.1 eq.) in DMF was added dropwise. After the addition, 
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the temperature was increased to 90 °C and the solution was stirred under argon 
overnight. The reaction was then quenched by the addition of a 50% aqueous NaCl 
solution, and the resulting mixture was extracted with CH2Cl2. The organic fractions were 
dried (Na2SO4), filtered, and concentrated under vacuum to yield the crude product, 
which was purified by column chromatography (SiO2, 0-5% MeOH in DCM) to afford the 
desired products as white solids in 20% yields. 
4-(4-(4-(4-((2-((1H-1,2,4-triazol-1-yl)methyl)-2-(3,5-dichlorophenyl)-1,3-dioxolan-4-
yl)methoxy)phenyl)piperazin-1-yl)phenyl)-1-((R)-2-hydroxypropyl)-1H-1,2,4-triazol-
5(4H)-one (163) 
1H NMR (500 MHz, CDCl3) δ 8.31 – 8.15 (m, 1H), 8.01 – 7.85 (m, 1H), 7.66 – 7.54 (m, 
1H), 7.54 – 7.38 (m, 1H), 7.25 – 7.02 (m, 1H), 6.97 (s, 5H), 6.95 – 6.78 (m, 3H), 4.81 (m, 
J = 25.3, 18.0, 9.1 Hz, 2H), 4.38 (m, J = 5.9 Hz, 1H), 4.26 – 3.97 (m, 1H), 3.93 (q, J = 
7.6 Hz, 1H), 3.82 (m, J = 14.6, 6.7, 3.8 Hz, 2H), 3.53 (m, J = 9.6, 4.7 Hz, 1H), 3.33 – 
3.16 (m, 8H), 1.64 (s, 1H), 1.27 (s, 1H). 
4-(4-(4-(4-((2-((1H-1,2,4-triazol-1-yl)methyl)-2-(3,5-dichlorophenyl)-1,3-dioxolan-4-
yl)methoxy)phenyl)piperazin-1-yl)phenyl)-1-((S)-2-hydroxypropyl)-1H-1,2,4-triazol-
5(4H)-one (164) 
1H NMR (500 MHz, CDCl3) δ 8.29 – 8.19 (m, 1H), 7.97 – 7.85 (m, 1H), 7.64 – 7.55 (m, 
1H), 7.49 (d, J = 2.0 Hz, 1H), 7.14 (d, J = 8.2 Hz, 1H), 6.97 (s, 4H), 6.90 – 6.74 (m, 5H), 
4.81 (m, J = 25.3, 18.0, 9.1 Hz, 2H), 4.38 (p, J = 5.9 Hz, 1H), 4.25 – 3.99 (m, 1H), 3.93 
(q, J = 7.6 Hz, 1H), 3.82 (m, J = 14.8, 6.6, 3.7 Hz, 2H), 3.53 (m, J = 9.6, 4.7 Hz, 1H), 
3.34 – 3.16 (m, 8H), 1.64 (s, 1H), 1.27 (s, 1H). 
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4-(4-(4-(4-((2-((1H-1,2,4-triazol-1-yl)methyl)-2-(3,5-dichlorophenyl)-1,3-dioxolan-4-
yl)methoxy)phenyl)piperazin-1-yl)phenyl)-1-((2S,3R)-2-hydroxypentan-3-yl)-1H-
1,2,4-triazol-5(4H)-one (165) 
1H NMR (500 MHz, CDCl3) δ 8.23 (s, 1H), 8.15 (s, 1H), 7.98 (s, 1H), 7.92 (s, 1H), 7.67 
(s, 1H), 7.60 (dd, J = 8.4, 2.5 Hz, 2H), 7.50 (t, J = 1.9 Hz, 1H), 7.48 – 7.42 (m, 2H), 7.28 
– 7.25 (m, 1H), 7.15 (d, J = 8.2 Hz, 1H), 7.09 – 7.02 (m, 2H), 7.00 – 6.93 (m, 2H), 6.86 – 
6.79 (m, 3H), 4.87 (d, J = 14.7 Hz, 1H), 4.81 – 4.74 (m, 2H), 4.39 (tt, J = 6.5, 4.9 Hz, 
1H), 4.26 – 4.14 (m, 2H), 4.09 (m, J = 11.0, 3.5 Hz, 2H), 4.02 – 3.79 (m, 4H), 3.76 – 3.67 
(m, 1H), 3.52 (dd, J = 9.7, 6.3 Hz, 1H), 3.44 – 3.35 (m, 5H), 3.30 – 3.23 (m, 5H), 2.05 
(m, J = 14.6, 11.0, 7.3 Hz, 1H), 1.90 (m, J = 14.7, 7.4, 3.6 Hz, 1H), 1.64 (d, J = 8.3 Hz, 
6H), 1.28 (d, J = 6.5 Hz, 5H), 0.94 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 
153.0, 152.7, 151.4, 150.8, 146.0, 136.1, 134.3, 134.3, 133.0, 131.4, 129.6, 127.3, 
127.3, 123.7 (2C), 118.5 (2C), 116.6 (2C), 115.3 (2C), 107.6, 107.2, 74.7, 70.3, 67.5, 
66.2, 61.6, 53.5, 50.6 (2C), 49.2 (2C), 31.6, 22.7, 19.5, 14.1, 10.8 . IR (film) ʋmax 3436, 
3181, 2933, 1646, 1511, 1456, 1385, 1348, 1277. DART-HRMS: m/z calculated for 
C38H43Cl2N6O5: 735.2577 [M+H]
+, Found: 735.2548. 
3. Biological evaluation 
3.1 Experimental protocols  
Analysis of Hh target gene expression: Cells were plated and grown according to 
cell line specific protocols described in Chapter 3. Recombinant SHh protein (200 ng/ ml) 
was used to activate Hh signaling in C3H10T1/2 cells. RNA isolation and evaluation by 
qRT-PCR analysis was performed as described in previous chapters. Data was 
analyzed using GraphPad Prism 5 and IC50 values computed as mean ± SEM from at 
least three separate experiments performed in triplicate.  
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3.2 Results 
Table 3. Preliminary evaluation of hybrid ITZ analogues. 
 
Analogue 
Gli1 mRNA IC50 Values (µM) 
C3H10T1/2 cells ASZ cells 
ITZ 0.074 ± 0.02 0.14 ± 0.02 
PSZ 0.01 ± 0.005 0.54 ± 0.05 
163 0.45 ± 0.09 0.15 ± 0.01 
164 0.18 ± 0.02 0.10 ± 0.01 
Preliminary evaluation conducted in C3H10T/12 cells revealed that both ITZ 
hybrid analogues maintain potent inhibition of Gli1 mRNA expression (180-450 nM). 
Overall, the (R) hydroxyl containing analogue i.e. 163 showed two-fold loss of activity as 
compared to the (S) hydroxyl derivative 164 in this cellular assay. The biological activity 
profile of these analogues showed similar trends when studied in the ASZ cells. Both 
derivatives strongly inhibited Gli1 mRNA expression in these cells as well (Table 3).  
4. Conclusion 
Discovery of potent Hh inhibitory activity mediated by ITZ opened new avenues for 
drug discovery explorations based on this scaffold. A comparative analysis of Hh 
inhibitory activities of various members from the azole class of antifungal drugs revealed 
PSZ to be an equipotent inhibitor of the Hh signaling cascade. This finding guided the 
design and development of next generation ITZ-PSZ hybrid analogues. However, the 
task of preparing such chimeric molecules entailed a challenging multi -step synthetic 
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route. Aiming to simplify this synthetic route for the purpose of easy and efficient 
medicinal chemistry investigations, necessary modifications to the existing synthetic 
strategy were planned and successfully executed. Preliminary evaluation of two new 
derivatives indicated that these hydroxylated side chain derivatives of ITZ maintain 
potent Hh inhibitory activity in vitro. Taken together, an optimized methodology for rapid 
synthesis of chirally defined hydroxylated side chain derivatives has led to the synthesis 
of active Hh inhibitors and will prove to be advantageous for the future production of 
related molecules. 
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CHAPTER V: Future Directions in the Development of Small Molecule Inhibitors of 
the Hh Pathway 
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1. Contributions of VD3 project 
The identification of aberrant Hh pathway signaling in a variety of human cancers 
led to a surge in research projects that focused on the development of pathway inhibitors 
as anti-cancer agents. Many of these initial drug discovery efforts focused on the 
development of small molecules that target Smo, the most druggable target within the 
pathway. Further, the FDA approval of GDC-0449 in early 2012 validated the clinical 
efficacy of treating Hh-dependent cancers with a Smo antagonist. Our initial efforts 
towards identifying improved Hh inhibitors began with studies based on VD3. To date, 
the molecular target for VD3 in the context of Hh signaling has not been confirmed. 
Therefore, in silico modeling or structure based drug designing was not feasible. Due to 
this challenge, a chemical-biology approach was adopted and implemented in order to 
successfully fulfill the goals of this project. Preliminary results suggesting that the 
metabolic conversion of VD3 to its physiologically active form, calcitriol, activates VDR 
signaling further led to the aim of repurposing the VD3 scaffold for selective Hh 
modulation. The knowledge gathered from probing in vitro biological models with VD3 
and its early analogues guided the design and discovery of improved next generation 
derivatives. One of the most significant outcomes of these studies was a better 
understanding of the structural requirements of VD3 for potent and selective Hh 
inhibition (Figure 1). The CD-ring region of VD3 was determined to be the necessary 
pharmacophore for Hh pathway inhibition. It was established that modifications of the A-
ring, seco B-ring and CD-ring side chain afforded greater selectivity for Hh modulation 
thereby diminishing the detrimental effects of concomitant VDR activation. Taking into 
account these key SAR findings, new VD3 based Hh antagonists were designed, 
prepared and evaluated. Among these novel analogues, 95, 100 and 104 afforded 
approximately four-fold improvement in Hh inhibitory activity while gaining greater than 
1000-fold selectivity for Hh signaling over the VDR pathway. 
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 Figure 1. SAR of VD3 for potent and selective Hh pathway inhibition.  
Another important contribution of this project was towards the optimization of in 
vitro assay systems for expedited evaluation of Hh inhibitors. Developing reliable cell 
based assays for monitoring endogenous Hh activity in cancer cell lines has proven to 
be a significant challenge. According to the generally accepted notion, the tumor 
microenvironment allowing cross talk with surrounding stromal cells is crucial for proper 
Hh signaling in several forms of cancer. Therefore, accurate in vitro evaluation of 
biological activities of potential Hh antagonists has been difficult owing to the lack of 
paracrine mode of Hh signaling in cultured epithelial tumor cells. This shortcoming was 
corroborated while working with human glioblastoma cell line U87MG to test A-ring 
analogues of VD3. Thereafter, a qRT-PCR based assay using MEFs such as 
C3H10T1/2 has been routinely employed for evaluating Hh inhibitors. Relatively higher 
time and resources consumed in this assay, which arises from using low RNA yielding 
MEF cells prompted us to search for suitable modifications to the assay protocol with the 
intention of developing a higher throughput assay. Consequently, the assay was 
optimized for a 96 or 24-well format to facilitate efficient screening of analogues with 
reliability and reproducibility directly from the cell lysate using commercially available 
Cells-to-CT kit (Life Technologies).  
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Since esterase enzymes are abundant in in vitro and in vivo systems, ester 
bonds are generally susceptible to metabolic cleavage under such environment. Thus, to 
avert metabolic liabilities, ester linkages are typically avoided in a drug molecule except 
when formulating a ‘pro-drug’. With these caveats in mind, we continued our exploration 
of VD3 SAR employing this class of ester linked analogues for a few different reasons. 
First, from a chemistry point of view, access to this group of analogues proved to be 
quick and efficient allowing expedited synthesis and investigation of biological activities. 
Next, based on distinct SAR trends it was established that observed activity is through 
the intact ester-linked scaffold and not the resulting metabolites 113, 114. Prior to 
conducting in vivo studies, it will be essential to identify and incorporate a linker less 
susceptible to metabolism while maintaining potent and selective Hh inhibition. 
Functional moieties such as amide, carbamate or ureido which are generally ‘drug like’ 
linker groups are proposed for this purpose and are being prepared currently by other 
researchers in the Hadden lab.  
A comprehensive understanding of the subcellular components that interact with 
VD3 is essential to developing VD3 analogues that exert their biological effects through 
selective inhibition of Hh signaling. Ongoing studies designed to explore the cellular 
mechanisms through which VD3 and its analogue 87 inhibit Hh signaling have focused 
on the two cellular receptors previously associated with VD3 i.e. VDR and Smo. 
Previously, tritiated analogue of VD3 was shown to selectively bind yeast cultures in 
which expression of human Smo had been chemically induced 107. In addition, this 
binding was antagonized by the addition of Cyc. On the contrary, results from our 
binding experiments suggest that neither VD3 nor 87 bind Smo in the Cyc binding 
pocket; however, this data does not preclude binding to another region of Smo 114. 
Preliminary analysis of VDR-mediated Hh inhibition for VD3 and 87 suggested that VDR 
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is required for the anti-Hh effects of VD3 but not for calcitriol or analogue 87. The 
inability of VD3 to maintain Hh inhibition in the presence of VDR knockdown was 
surprising for several reasons. First, similar studies performed in ASZ cells utilizing VDR-
specific shRNA demonstrated that VDR knockdown did not affect the ability of VD3 to 
down-regulate Gli1 mRNA expression 110. In addition, as demonstrated by our lab 108 and 
others, 171 calcitriol inhibits Hh signaling in vitro and in vivo and these anti-Hh effects of 
calcitriol were not abrogated in Vdr −/− fibroblasts 171. More specifically, the ability of 
calcitriol to inhibit Hh signaling in vitro has been localized to a step downstream of Ptch, 
suggesting its effects may also be mediated via Smo. As our assays (C3H10T1/2) and 
those previously reported (ASZ and fibroblasts) were performed in different cell lines, it 
is clear that cellular context is essential for determining the mechanisms through which 
VD3, calcitriol, and their analogues inhibit Hh signaling. Therefore, the development of 
chemical probes that can definitively identify binding interactions will be necessary to 
further our understanding of whether the anti-Hh effects of these sterols are mediated 
via direct binding to Smo, or another, as yet unidentified, mechanism. 
2. Contributions of ITZ project 
Following the identification of ITZ as a potent Hh/Smo antagonist, several new 
clinical trials have been initiated to assess the implications of repurposing this antifungal 
drug for the treatment of Hh-driven cancers. Along with promising initial results from 
these studies, an additional factor in favor of ITZ is its potent anti-Hh activity against the 
known drug resistant forms of the signaling cascade 101, 117. Irrespective of the final 
consequences of current clinical trials, the ITZ scaffold is certainly a promising new drug 
lead for the development of Hh inhibitors. Therefore, we examined possible design 
strategies to develop ITZ based analogues for the inhibition of Hh signaling.  
 103 
 
During a comparative analysis of several azole antimycotic drugs, it was revealed 
that PSZ exhibits potent Hh inhibition similar to ITZ. Hence, we prepared three 
analogues that incorporate stereochemically defined hydroxylated side chains 
reminiscent of the PSZ side chain to determine whether this enhanced Hh inhibitory 
activity is mediated through the side arm region. Also, these analogues were designed 
with the objective of enhancing water solubility of the otherwise poorly soluble ITZ 
molecule. After several rounds of optimization with respect to previously reported 
synthetic routes to either ITZ or PSZ, rapid access to this class of compounds was 
accomplished. 
With a protocol in place for the synthesis of chimeric ITZ-PSZ analogues, future 
efforts can be directed towards preparing related analogues (Figure 2). This class of 
analogues will provide SAR inferences regarding the effects of defined stereochemistry 
of the side chain on Hh inhibition. Further, evaluation of potent analogues against drug 
resistant forms of Smo will aid the identification of ideal candidates for advanced 
development. 
 
Figure 2. Additional side chain analogues of ITZ.  
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3. Future outlook for the discovery and development of Hh pathway inhibitors 
The recent identification of multiple mechanisms that can result in resistance to 
Smo antagonists has led numerous researchers to target additional pathway 
components. The general consensus has been that small molecules acting on targets 
downstream of Smo, particularly at the level of the Gli transcription factors or on distinct 
binding sites of Smo, hold more promise for resistant forms of Hh-dependent cancers. 
Several research groups have identified pathway inhibitors that function through 
inhibition of Gli function; however, the majority of these have only demonstrated modest 
inhibitory activity in vitro and in-depth SAR, mechanism of action, and in vivo studies for 
these compounds have not been reported. The last year has seen numerous structural 
reports detailing several distinct small-molecule binding sites on Smo. Understanding 
key molecular interactions between Smo antagonists and these binding sites may also 
facilitate the design of small molecules with enhanced potency against resistant forms of 
Smo. Meanwhile, a combination therapy approach has shown reasonable success in 
inhibiting resistant forms of Hh signaling in human cancer. For instance co-
administration with verapamil, an inhibitor of P-gp, restored the anti-Hh activity of IPI-926 
in murine MB that had developed resistance due to IPI-926-induced overexpression of 
P-gp 37. In a separate study, co-administration of NVP-LDE225 with either the PI3K 
inhibitor NVP-BKM120 or the dual PI3K-mTOR inhibitor NVP-BEZ235 significantly 
delayed the development of resistance and enhanced MB tumor regression in animal 
models 35. Similarly, small molecule inhibitors of Aurora kinase or Polo-like kinase 
demonstrated potent anti-tumor effects in vitro and in vivo in murine Ptch-/- MB both 
alone and in combination with NVP-LDE225 172. A related combination approach that 
utilized two pathway inhibitors that act through diverse mechanisms has also proven 
effective. Combined oral administration of ITZ and ATO in a subcutaneous allograft of 
SmoD477G-driven MB demonstrated potent inhibition of both Hh signaling and tumor 
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growth 101. While these combination studies have proven effective in a preclinical setting, 
their advancement into clinical trials is necessary to definitively evaluate their ability to 
inhibit resistant forms of Hh signaling in human cancer.   
In addition to the issues associated with acquired resistance to Smo antagonists, 
another limitation associated with the development of pathway inhibitors is related to 
their general application across a wide-range of human cancers. While aberrant Hh 
signaling has been implicated in various forms of human cancer, the scope of using Smo 
antagonists as a monotherapy has proven limited. To date, only BCC and MB, 
malignancies that are driven by specific mutations in Ptch, Smo, or Sufu have proven 
amenable to this type of therapeutic intervention. IPI-926 was withdrawn from several 
Phase II trials for failing to meet its endpoint against cancers that are not generally 
considered to be strictly Hh-dependent. In addition, the anti-cancer activity of pathway 
inhibitors in vitro and in vivo in non-Hh-dependent cancers is often not correlative with 
their anti-Hh effects 12, 108. Again, there have been increasing reports in which a Smo 
antagonist used in combination with another small molecule has demonstrated 
promising preclinical or clinical activity. Specific examples include the clinical studies of 
notch inhibitor RO4929097 combined with GDC-0449 in treating advanced or metastatic 
sarcoma based on the fact that both of these signaling mechanisms are responsible for 
sustaining sarcoma tumors 173. Similarly, promising results have been reported in 
combining GDC-0449 with gemcitabine and nab-paclitaxel against advanced pancreatic 
cancer 174.  
As a whole, these results clearly highlight the anti-cancer potential of Hh pathway 
inhibitors in Hh-dependent cancers, as well as the potential of combination regimens in 
resistant or non-Hh-dependent cancer. Moreover, they also emphasize the need for 
continued development to ensure there will be effective treatments for future patients 
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who experience detrimental side effects or are not responsive to the compounds 
currently under development. 
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APPENDIX A: Selected 1H & 13C NMR Spectral Data 
 
 
 
 
 




































